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7SUMMARY
Neurodegenerative diseases associated with dementia affect 5-10 % of individuals over
the age of 65 in the Western world and represent one of the main health-related socio-
economic burdens. The most common form of dementia, Alzheimer’s disease (AD),
affects 98000 people in Switzerland, with 23000 newly diagnosed cases each year
additionally underscoring the importance of understanding its pathogenesis with the
ultimate goal of developing efficient therapeutic strategies.
Neuropathologically, AD is characterized by the extracellular deposition of Amyloid-β
peptide (Aβ) and the intracellular aggregation of hyperphosphorylated Tau protein.
Early-onset AD, which accounts for only 6%-7% of all AD cases, is generally defined as
occurring before the age of 60 and is due to hereditary mutations in genes that promote
the deposition of Aβ. Based on these familial AD cases (FAD), the ‘Amyloid cascade’
hypothesis was formulated, postulating that deposition of Aβ, which triggers subsequent
Tau pathology, is at the heart of AD pathogenesis. However, somewhat contradictory to
this hypothesis, abundant filamentous Tau deposits and neuronal damage can also occur
in the absence of Aβ pathology and are in fact key features of a heterogeneous group of
neurodegenerative disorders termed ‘tauopathies’. In the late nineties, the discovery of
multiple mutations in the Tau  gene underlying a particular condition called
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17)
provided direct evidence that mutant Tau dysfunction per se is sufficient to cause
neurodegeneration. Of note, in AD and many other tauopathies, Tau pathology spreads
intracerebrally following a stereotypical temporo-spatial pattern that correlates well with
the cognitive impairment of affected patients. Intriguingly, however, the mechanisms by
which Tau pathology initiates and spreads within the brain remain largely unknown so
far.
The present research project therefore focused on the experimental induction and the
spreading of Tau pathology. Taking advantage of several transgenic mouse models that
exhibit neuropathological characteristics of AD and tauopathies, we aimed to elucidate
the relative contributions of Aβ and Tau, respectively, to disease pathogenesis.
8In particular, we employed the APP23 mouse model where a mutated human amyloid
precursor protein (APP), the so-called Swedish mutation, is transgenically expressed.
These mice develop Aβ plaques at 6 months of age in association with the typical AD-
associated pathology including cerebral amyloid angiopathy (CAA), neuron loss, glial
activation, and cognitive impairment.
Moreover, we also studied various Tau transgenic mouse models including the JNPL3
strain, which harbours the human FTDP-17-associated P301L Tau mutation and which
develops NFTs by the age of 6.5 months. We backcrossed this line to the C57Bl/6J
background (B6/P301L). B6/P301L heterozygous females developed a delayed
filamentous Tau pathology, occurring at around 17 months of age, which might represent
a particularly suitable animal model to experimentally modulate the onset of tauopathy.
Surprisingly, heterozygous B6/P301L male mice developed only little Tau pathology by
the age of 26 months, restricted to the spinal cord and the brain stem.
In addition, we took advantage of the P301S mouse line transgenically expressing the
FTDP-17-linked P301S mutation. These mice develop abundant filaments made of
hyperphosphorylated Tau protein and become severely paralyzed by 5-6 months of age
due to a high load of fibrillar Tau pathology in the brain stem and spinal cord. Finally, we
used the ALZ17 mouse model which transgenically expresses the human wild-type Tau
protein. These mice develop abnormal Tau hyperphosphorylation in the absence of Tau
filaments or neurodegeneration, and therefore lend themselves as so-called ‘pre-tangle’
mice. This model is of particular interest for studying the pathological steps leading to
Tau fibrils formation.
The first part of the experimental studies was centred on the in vivo relationship between
Aβ and Tau pathologies. In our initial study, we used lentivirus technology for its ability
to infect nondividing cells and to stably maintain long-term transgene expression in
specific brain regions. Lentivirus-mediated expression of the mutated human Tau protein
(LV-hTauP301S) was assessed in the brains of both wild-type and APP23 mice. Injection
of LV-hTauP301S into the hippocampus of wild-type as well as APP23 mice led to
strong and stable transgene expression for more than one year. In addition,
hyperphosphorylation of Tau was induced in both mouse lines as early as 3 months post-
9injection, while no Tau aggregation was observed in wild-type animals up to 13 months
of mutated Tau transgene expression. In contrast, APP23 mice injected with LV-
hTauP301S developed Gallyas-positive neurons indicative of the formation of Tau
filaments. We concluded from these findings that Tau aggregation can only be induced in
an environment rich in Aβ deposits, also supporting the notion that APP and/or Aβ
promote Tau pathology.
In another set of experiments, we tested alternative approaches to study the induction of
Tau pathology. In particular, we performed a series of cortical as well as
intrahippocampal injections of brain extracts bearing Aβ pathology and/or Tau pathology
into young B6/P301L animals. Aβ extracts were prepared from old APP23 mice whereas
Tau extracts were derived from aged B6/P301L animals. Brain extracts from human AD
patients (containing both Aβ and Tau pathology) were also injected into P301L/B6 mice.
Six months after infusion with Aβ-containing extracts, we found an induction of Tau
pathology not only in the injected hippocampus but also in the entorhinal cortex and
amygdala. In contrast, intracerebral injection of Tau-containing extracts produced only
limited Tau deposition. In parallel to these brain extract injection experiments, a breeding
approach was used to study the relationship between Aβ and Tau pathology by mating
B6/P301L with APP23 transgenic mice. Significantly, double-transgenic mice developed
increased fibrillar Tau pathology when compared to single B6/P301L-transgenic mice,
especially in areas with Aβ deposition. Collectively, these results demonstrated that both
injection of Aβ-containing extract and deposition of Aβ fibrils can induce intracellular
aggregation of Tau.
Finally, we investigated the Aβ-independent induction of tauopathy by injecting murine
P301S brainstem extract rich in Tau filaments into the cortex and hippocampus of young
ALZ17 mice expressing wild-type human Tau. We observed filamentous Tau pathology
as early as six months after injection with fibrillar Tau induction occurring not only in
neurons but also in oligodendrocytes. Strikingly, filamentous Tau was not restricted to
injection sites but also stereotypically developed in discrete brains regions over time, a
finding which – for the first time – clearly demonstrated the transmission and spreading
of filamentous Tau pathology in vivo.
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Altogether, the studies comprised by the present thesis aim to contribute to a better
understanding of Tau pathology induction and its pathogenic relation to Aβ. We have not
only demonstrated that Aβ deposits are able to potentiate Tau pathology but also that
pathological Tau per se can induce Tau aggregation. The latter observation may provide
the basis for future studies of the transmissibility of Tau pathology with special regard to
potential similarities and differences in comparison to classical prion diseases.
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1. INTRODUCTION
1.1. Tau protein
In 1975, Weingarten et al. isolated a factor that induces microtubule assembly and called
it Tau for its ability to promote tubule formation [1]. Tau was described as an extremely
heat stable protein that controls the polymerization of microtubules as major component
of nerve axons implicated in transport and neurotransmission. This discovery was the
first example of a protein other than tubulin that was later proven to be essential for the
assembly of microtubules. However, Tau remained largely neglected by the field until it
was found to be associated with the neurofibrillary lesions encountered in the brains of
patients who suffer from Alzheimer’s disease [2-6], a discovery that led many research
groups to study the metabolism and function of Tau protein.
1.1.1. The Tau gene gives rise to different Tau isoforms
A unique gene encodes for Tau protein in the human [7], rat [8] and bovine [9] genomes. In
human, where it contains 16 exons, it has been localized to chromosome 17q21.1 [7]
(Figure 1). In analogy to more than 60% of human genes [10], Tau is alternatively spliced,
giving rise to three transcripts of 2, 6, and 9 kb of distinct exon composition encoding
multiple different protein isoforms [11-16].
Nuclear Tau
A tau transcript of 2 kb has been detected in cultured human cells and human frontal
cortex [11]. The 2 kb message encodes for ubiquitous nuclear Tau and arises from the
original tau transcript [11, 17-19]. This nuclear isoform is highly insoluble and present in
mitotic cells within nuclear organizer regions of the acrocentric chromosomes (numbers
13, 14, 15, 21 and 22), where rRNA genes are located [20]. Nuclear Tau specifically binds
to AT-rich satellite DNA sequences, which form the centromere of mammalian
chromosomes [21], and may function in nuclear remodelling and/or ribosomal synthesis.
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Tau in the peripheral nervous system (PNS)
A 9 kb mRNA restricted to the retina and the PNS encodes for a much larger-sized
variant of Tau that has an apparent molecular mass of 110 kDa [12, 15, 18]. In this mRNA
exons 2 and 3 are constitutively expressed as well as exon 4A, which by itself codes for
254 amino acids [12, 15, 22]. This Tau variant has been identified in various cell types,
including mature dorsal root ganglion cells, sympathetic neurons, as well as the rat
pheochromocytoma cell line PC12 [23-26], where it is thought to serve an important role in
stabilizing the neuronal cytoskeleton [22, 25].
Tau in the central nervous system (CNS)
The human 6 kb mRNA is restricted to the CNS and codes for axonal Tau. Among the 16
exons of the primary transcript, exons 1, 4, 5, 7, 9, 11, 12, and 13 are constitutive in CNS
tau, whereas exons 2, 3, and 10 are alternatively spliced and are adult-specific [13, 14, 27].
The mRNA undergoes complex splicing leading to the production of six Tau isoforms
(Figure 1) [13, 14, 28]. On the protein level, these variants range from 352 to 441 amino
acids with a molecular weight from 45 to 65 kDa, with further complexity arising from
the presence (or absence) of a 29- or 58-amino acid insert in the amino terminal (N-
terminal) half of the protein, encoded by exon 2 and/or 3 [13, 29, 30]. Whereas exon 2 can be
expressed without exon 3, expression of exon 3 is always coupled to that of exon 2. All
six CNS Tau isoforms contain at least three repeat domains (R1, R3 and R4) in the
carboxy terminal (C-terminal) part and the inclusion of exon 10 leads to three isoforms
each containing a fourth repeat domain (R2) of 31 amino acids [13, 29, 30]. Tau expression is
developmentally regulated and only the shortest Tau isoform, characterized by the
absence of N-terminal inserts and the presence of three C-terminal repeats is expressed in
developing human brain [14, 30]. The six isoforms are not equally expressed in neurons: for
instance, tau mRNA containing exon 10 is not found in granule cells of the dentate gyrus
[14].
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1.1.2. Structure and functions of the different domains of Tau
Tau is a tripartite protein composed of a C-terminal region harbouring varying numbers
of repeat domains, a constant middle domain rich in proline, and variable N-terminal
domains (Figure 1) [29].
The C-terminal domain
As previously mentioned, Tau proteins are microtubule-binding proteins that promote
tubulin assembly [1, 31]. This property is attributable to repetitive sequences of 31 or 32
residues located within in the C-terminal half of the protein [29, 32, 33]. These repeats can be
divided in two parts, one composed of an 18 amino acid sequence containing the region
with tubulin binding activity and a second composed of 13 or 14 amino acid inter-repeat
regions [9, 13, 14, 29, 30, 34]. The repeat sequences are encoded by exons 9-12 among which
exon 10 is alternatively spliced [14, 35] and leads to the insertion of a fourth repeat, R2,
which increases the affinity of Tau for microtubules [14, 30, 33, 34]. Each repeat binds to an
adjacent tubulin molecule, thereby tethering microtubule together and limiting their
freedom of movement relative to one another [36]. Expression of exon 10 is
developmentally regulated and may be important during the transition from the more
fluid foetal cytoskeleton, which requires plasticity, to the more stable adult one.
The N-terminal domain
The two 29 amino acids inserts encoded by exons 2 and 3 result in different lengths of the
N-terminal domain of Tau and render it more acidic [37]. This part of Tau is called the
projection domain as it forms short arm-like projections important for Tau anchoring to
microtubules [38]. This structural property determines microtubule spacing and influences
axon diameter [37], which is of particular importance in the PNS, where large diameter
axons are required. It depends on the expression of exon 4A in PNS Tau, which gives rise
to projection domains twice as long as those of CNS Tau [28, 39]. Through these molecular
modifications Tau functions as an important regulator of axonal size and stabilizer of the
axonal cytoskeleton of different axon types. In addition, the N-terminal domain of Tau
interacts with the plasma membrane and cytoskeletal elements such as spectrin, actin, and
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neurofilaments [40-46]. Via these interactions, Tau mediates associations between
microtubules and other components of the cytoskeleton. Interestingly, Tau also binds to
the plasma membrane at the periphery of growth cone-like structures in differentiating
PC12 cells suggesting a role of Tau in neuritic development [40].
The proline-rich middle domain
The middle domain of Tau (proline-rich) interacts with so-called SH3 domains present in
several proteins. These SH3 domains, first identified in the non-receptor tyrosine kinase
src family, mediate protein-protein interactions and recognize proline-rich regions [47, 48].
For instance, Tau interacts with fyn, a member of the src family, by a PXXP (residues
233-236) motif that binds to the SH3 domain of fyn [49, 50]. This interaction takes place
just beneath the plasma membrane in association with actin filaments [49]. Thus, Tau is
assumed to be a key component of a fyn-associated signalling pathway that modulates
cell shape by impinging on the submembranous actin cytoskeleton [49]. Proline-rich
sequences of Tau also interact with the SH3 domain of phospholipase C-γ (PLC),
localized in the plasma membrane [51]. Tau activates PLC-γ towards phosphatidylinositol
4,5 bisphosphate (PIP2), which is potentiated by the presence of arachidonic acid [51, 52].
Interestingly, the middle domain of Tau also plays a role in microtubule binding. The
proline-rich domain causes a strong increase in the efficiency of microtubule assembly
when joined to the inter-repeat sequences between R1 and R2 (Figure 1) [53]. These
flanking regions are important for Tau intramolecular interactions [54, 55]. Interestingly, the
proline-rich region per se binds very weakly to microtubules but its deletion from Tau
dramatically decreases microtubule-affinity in vitro and in vivo [32, 56-59].
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Figure 1. Tau gene, primary transcript and isoforms of human brain Tau
The human Tau gene spans over 100kbp on chromosome 17 at the position q21. It
contains 16 exons, exon -1 being part of the promoter. The start codon is located in exon
1 and the initiation of the transcription is indicated by +1. Exons 4A, 6 and 8 are
generally not spliced into human brain tau mRNA and most transcripts retain the intron
between exons 13 and 14. (upper panel). In the CNS, the human primary transcript
contains 13 exons. (middle panel). The alternative splicing of exons 2 (yellow box), 3
(green box) and 10 (slashed box) gives rise to 6 different CNS adult Tau isoforms (lower
panel). They range from 352 to 441 amino acids and differ by the presence or absence of
1 or 2 N-terminal inserts (N) in combination with either 3 or 4 repeats (R, black boxes) in
the C-terminal region of the protein. They are composed of three domains, a N-terminal
acidic domain, a proline-rich region and a C-terminal repeat domain. The splicing in exon
10 leads to the insertion of the second repeat (R2). Its presence increases the binding to
microtubules. The shortest 352 amino acids isoform (0N/3R) is the unique Tau protein
present in the foetal brain. (Adapted from Buée et al, 2000 [60]).
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1.1.3. Tau phosphorylation
The phosphorylation of Tau constitutes its main post-translational modification [44, 61].
Phosphorylation sites on the Tau molecule include serine (Ser) or threonine (Thr)
residues followed by proline (Pro) (the longest form of human brain Tau has eighty Ser
or Thr residues) [13]. A large number of potential phosphorylation sites are easily
accessible due to the open structure of Tau. This feature suggests implication of a
subgroup of kinases specific for Ser-Pro or Thr-Pro motifs, so-called proline-directed
protein kinases (PDPK). On the other hand, Tau phosphorylation can also occur on Ser or
Thr residues that are not followed by Pro, by non-proline-directed protein kinases (non-
PDPK). Although more than a dozen protein kinases have been shown to phosphorylate
Tau in vitro, only few appear to be suitable candidates for in vivo phosphorylation.
Glycogen synthase kinase 3β (GSK3β)
This kinase, which phosphorylates both non-Ser/Thr-Pro and Ser/Thr-Pro sites, is
expressed at high levels in neurons where it associates with microtubules, and thus is
present in the appropriate compartment to access Tau [62-64]. Currently, it appears to be the
most obvious candidate for in vivo phosphorylation of Tau. Overexpression of GSK3β in
cells or in the brains of transgenic mice leads to an increase of Tau phosphorylation [65-69].
In addition, treatment of cells with lithium, which inhibits GSK3β, significantly reduces
Tau phosphorylation [70-72]. However, as GSK3β acts on different other proteins,
additional studies need to define the direct or/and indirect pathways of GSK3β-mediated
Tau phosphorylation [73-76].
Cyclin-dependent kinase 5 (Cdk5)
As a member of the cyclin-dependent kinase family, Cdk5 is apparently not involved in
cell-cycle regulation. Its activity is high in neurons due to the presence of its regulator
p35 [77, 78]. Truncation of p35 produces the more stable p25, which forms a complex with
Cdk5, resulting in Tau phosphorylation at specific sites [79-81]. However, conflicting data
emerged concerning the activity of Cdk5 on Tau and it remains to be determined if this
kinase directly contributes to Tau phosphorylation [82].
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The non-receptor tyrosine kinase fyn
In addition to phosphorylation at Ser and Thr, Tau is also phosphorylated at tyrosine
(Tyr) residues [83]. As fyn binds to Tau, it has been hypothesized to be the kinase that
phosphorylates Tyr18 [49, 83]. In addition, fyn phosphorylates GSK3β, which in turn
becomes activated and increases Tau phosphorylation [84]. Therefore, fyn not only
mediates phosphorylates of Tau at Tyr18 but also indirectly increases Tau
phosphorylation via GSK3β.
Additional kinases implicated in Tau phosphorylation
In addition to the kinases discussed above, it has been shown in vivo that Tau can also be
phosphorylated at the KXGS motifs present in each microtubule-binding repeat of the
protein [85]. Microtubule-affinity-regulating kinase (MARK) phosphorylates KXGS
motifs more efficiently than other protein kinases suggesting that MARK could be a Tau
kinase [85-88]. Other data exist to indicate that Tau is phosphorylated by cAMP-dependent
kinase (PKA) or calcium/calmodulin-dependent kinase II (CamKII) in vivo [89-92]. In
addition, members of the mitogen-activated protein kinase family (MAPK) have also
been linked with Tau phosphorylation. They include the stress-activated C-Jun N-
terminal kinase (SAPK/JNK), p38 mitogen-activated protein kinase (p38 MAPK), and
the extracellular signal-regulated kinase 2 (ERK2) [93-95].
However, the role of potential Tau kinases in modulating Tau phosphorylation under
various physiological and pathophysiological conditions still needs to be established in
vivo using appropriate experimental models.
Phosphatases
All major protein phosphatases (PPs) have been implicated in Tau dephosphorylation [96-
99]. PP1 indirectly dephosphorylates several Tau residues via regulation of GSK3β and
Cdk5, whereas PP2A appears to dephosphorylate the same sites directly [100]. In
particular, PP2A has been shown to act by attaching to Tau microtubule-binding domains
thereby rendering the binding of Tau to microtubules impossible [101]. In addition, PP2A
has also been shown to dephosphorylate Tau indirectly through CamKII inhibition [102].
Phosphatase activity on Tau has also been demonstrated for PP2B, affecting other sites
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than those targeted by PP1 and PP2A [89]. Finally, PP5, a phosphatase highly expressed in
brain neurons, was shown to counteract Tau phosphorylation by PKA and GSK3β [103].
Additional candidates, which efficiently dephosphorylate Tau in vivo, still wait
identification.
1.1.4. Physiological roles of Tau phosphorylation
Phosphorylation of Tau is developmentally regulated. For example, the foetal short Tau
isoform is highly phosphorylated, especially at sites important for microtubule binding [85,
104-106]. Tau, when phosphorylated within the C-terminal repeat domains, has a reduced
ability to bind to and polymerize microtubules when compared to non-phosphorylated
Tau [65, 107-111]. This is of particular importance during the cell cycle where Tau
phosphorylation is synchronized with cell division phases. During interphase, the
majority of Tau proteins are poorly phosphorylated and associate with microtubules to
maintain the cytoskeleton, whereas during mitosis Tau phosphorylation increases [112] and
the protein subsequently detaches from microtubules which enables their reorganization
[113]. Interestingly, during axon formation, there is a gradient in Tau phosphorylation from
proximal where Tau is highly phosphorylated, to distal where only 20% of Tau is
phosphorylated [114, 115]. The modulation of this proximo-distal gradient in Tau
phosphorylation could contribute to (or even underlie) neuronal polarity. Furthermore,
neurite outgrowth is locally regulated by phosphorylation of Tau within its microtubule-
binding domains [88, 116, 117].
These observations reflect the highly dynamic structure of microtubules during
development and underline the important role of Tau phosphorylation in neuronal
differentiation and plasticity.
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1.1.5. Pathological phosphorylation and aggregation of Tau
Whereas phosphorylation is fundamental for Tau function in physiological conditions, a
large number of neurodegenerative diseases features neurofibrillary lesions composed of
Tau in an abnormal phosphorylated state (see chapter 1.2.). This pathological
phosphorylation of Tau, assumed to result from deregulation of Tau kinases or/and
phosphatases, can occur either at sites that are normally phosphorylated, or at residues
that do not undergo phosphorylation under physiological conditions [80, 102, 106, 118-124].
Abnormal phosphorylation of Tau dissociates it from microtubules, causing its
redistribution from axonal to somatodendritic compartments, which is characteristic of
the ‘pretangle stage’. Consequently, the increased pool of hyperphosphorylated Tau is
thought to promote the ‘tangle stage’-specific Tau aggregation [125]. Whereas both
pretangle and tangle stages can be visualized by phosphorylation-dependent antibodies
like AT8 [126], only the tangle stage can be specifically detected by silver staining
techniques such as the Bielschowsky and Gallyas methods [127, 128] or by conformation-
dependent antibodies such as AT100 [129] (Figure 2).
Ultrastructurally, Tau aggregates into filaments that mainly appear as two strands twisted
around each other thereby forming the so-called paired-helical filaments (PHF), whereas
a minority of filaments are straight, as if two strands ran parallel to each other, or twisted
ribbons filaments [130-134]. Electron microscopy reveals that PHFs are composed of a
‘core’ region composed of the repeat domains that consists of cross-β structure, and a
largely disordered ‘fuzzy’ coat made of the rest of the protein that retains its natively
unfolded character [135-137]. This aggregation is triggered by its dimerization, which occurs
via nascent β-structures present within the repeat domains and is accompanied by a
conformational change that brings the N-terminal domain into close proximity to the
microtubule binding repeats [138-147]. Assembly studies revealed that after formation of
Tau dimers a kinetic barrier prevents the rapid formation of filaments, thus suggesting a
nucleation step [148, 149]. After the formation of the nucleus, filaments grow in an
exponential growth phase with predominant filament extension, followed by a plateau
phase, during which the rates of promoter association to and dissociation from filament
ends balance each other [150, 151].
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A feature of many amyloid deposits is that protein fibrils are enriched in β-sheet content
[152].  Thus, abnormal Tau  filaments formed in neurodegenerative diseases can be
considered as ‘amyloids’ and understanding the mechanisms leading to Tau aggregation
will undoubtedly contribute to the development of strategies aimed at preventing
neuronal degeneration.
Figure 2. Hyperphosphorylation of Tau precedes its aggregation
Pretangle neuron containing Tau in a hyperphosphorylated but non-aggregated state
visualized by phosphorylation-dependent antibody AT8; this neuron is Gallyas negative
(left panel). Neurofibrillary tangle, composed of aggregated Tau, stained by Gallyas
silver technique (middle panel). The image on the right is a scanning electron
microscopy picture of paired-helical filaments (picture from Itoh et al. 1997 [153]).
21
1.2. Neurodegenerative disorders with Tau pathology
Pathological Tau aggregates are encountered in a large number of neurodegenerative
diseases grouped under the convenient term ‘tauopathies’ (Table 1) [154]. Only the most
frequent of them will be shortly described here.
(Adapted from Lee et al. 2001 [154])
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1.2.1. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of
people worldwide. The history of AD started in 1901 when the German psychiatrist Alois
Alzheimer (1864-1915) (Figure 3) began to be involved in the observation of a 51-year-
old female patient, Auguste D (Figure 3) [155]. Her first symptoms included changes in
personality with strong feelings of jealousy toward her husband. Over one year, this
patient developed a serious impairment in new memory formation that was followed by
hallucinations, paranoid ideas, speech difficulties and behavioural problems [155]. After
her death in 1906, Alzheimer published a clinicopathological description of her illness
[156-158]. By the use of a silver staining method described by Max Bielschowsky (1869-
1940), he found abundant senile plaques and neurofibrillary tangles (NFT) in the cerebral
cortex [159]. Blocq and Marinesco, however, had described these plaques already
previously in an epileptic patient but Alzheimer was the first to discover the tangle
pathology [160] (Figure 3).
Figure 3. Alois Alzheimer and Auguste D.
Alois Alzheimer (1864-1912) (left image) and his first patient, Auguste D., in whom he
described the typical lesions of the disease now bearing his name. On the right the
original drawing by Alois Alzheimer showing the neurofibrillary lesions present in this
patient’s brain is depicted.
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1.2.1.1. Neuropathological hallmarks
The plaques and tangles that were observed in the brain of Alzheimer’s original patient
are still the two undisputed histopathological hallmarks of AD. Neuropathologically, they
are accompanied by variable neuronal losses in the entorhinal cortex, hippocampus, and
cerebral cortex [161]; synaptic damage [162-164]; loss of cholinergic innervation [165]; and
signs of inflammation [166].
Aβ deposits and APP processing
The senile plaques are composed of extracellular deposits of aggregated amyloid-β
protein (Aβ), surrounded by dystrophic neurites, activated microglial cells and reactive
astrocytes [167, 168]. Aβ deposits are also encountered in diffuse plaques that present a
more amorphous profile and lack Aβ fibrils [169, 170] and in the walls of cerebral and
leptomeningeal blood vessels, also called cerebral amyloid angiopathy (CAA) [171, 172]
(Figure 4).
Figure 4. Extracellular deposition of Aβ
Immunohistochemistry for Aβ showing the main types of extracellular deposits
encountered in AD. Senile plaque with amyloid core (left), diffuse plaque (middle) and
Aβ deposition in vessel walls (cerebral amyloid angiopathy; right).
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The major component of β-amyloid plaques is the Aβ peptide, which results from the
proteolysis of the amyloid precursor protein (APP) [173-176]. APP is a transmembrane
glycoprotein that can be proteolytically processed by α-, β-, and γ-secretases. The α-
secretase constitutively cleaves APP within the Aβ region to produce soluble α-APP and
the 83-residue C-terminal fragment, C83 [177, 178]. In contrast to α-secretase cleavage,
cleavage by β-secretase is amyloidogenic, generating the soluble β-APP and the C99
fragment [179]. Both C83 and C99 are membrane-anchored and may become degraded by
γ-secretase to produce either p3 or Aβ, respectively (Figure 5). γ-secretase forms a large
heterotypic complex required for its activity, which is composed of presenilin (PS),
nicastrin, PEN-2, and APH-1 [180-184]. Presenilins act as catalytic subunits of γ-secretase
[185]. γ-secretase cleavage is not sequence-specific, and produces various Aβ peptides with
Aβ40 being the most common, followed by Aβ42. The latter is the predominant form in
senile plaque cores, more prone to aggregate into toxic fibrils than Aβ40 [186-188]. The
formation of Aβ fibrils follows a nucleation or seeding mechanism that implies the
formation of oligomers [189]. These oligomers are thought to act as seeds and to recruit
further monomers that self-organize into protofibrils and fibrils made of β-sheet
structures [190]. In AD, oligomeric Aβ is more toxic than its monomeric form and fibrils
made of both Aβ peptides (Aβ40, Aβ42) contain β-sheet structures classifying them as
amyloids [191-194].
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Figure 5. APP processing
The amyloid peptide includes 28 residues outside the membrane and its first 12-14
residues of the transmembrane domain. Cleavage by α-secretase (left panel) secretes the
large and soluble APP intracellular domain (AICD) into the cytoplasm and retention of
the 83-residue C-terminal fragment (C83) in the membrane. C83 can undergo cleavage
by γ-secretase to release the p3 peptide. Cleavage by β-secretase (right panel) results in
the secretion of AICD and the retention of a 99-residue C-terminal fragment in the
membrane. C99 can also undergo cleavage by γ-secretase to release the Aβ peptides that
can aggregate into amyloid deposits. Amyloidogenic peptides in red. (Adapted from
Kahle et al, 2003 [195]).
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Neurofibrillary lesions
The second hallmark of AD is the presence of intracellular deposits of
hyperphosphorylated Tau proteins in neurofibrillary tangles (NFT), neuropil threads (NT)
and dystrophic neurites that are associated with senile plaques. In NFTs, Tau lesions are
located in the somatodendritic compartment, whereas in NTs, they are found in distal
dendrites and axons (Figure 6).
Figure 6. Intracellular lesions made of Tau protein
Gallyas silver staining in the neocortex of an AD brain. Left panel: neurofibrillary
tangles (arrows) and neuropil threads (arrowheads). Right panel: dystrophic neurites
surrounding senile plaques (arrowheads).
27
1.2.1.2. Aβ cascade hypothesis
Aβ has been in the main focus of AD research since it is generally considered as the
upstream causative factor for tau pathology and other neurodegenerative changes [196].
This ‘amyloid cascade hypothesis’ derives from molecular genetic studies that had
identified three genes associated with early onset familial AD (FAD) cases: APP, PS1,
and PS2 [197, 198]. Mutations in one of these genes cause FAD in an autosomal-dominant
manner by affecting the processing of APP and Aβ production. Mutations in the APP
gene, located on chromosome 21, lead to an increase in total Aβ levels [199]. In addition,
in Down’s syndrome (trisomy 21), the extra copy of chromosome 21 results in increased
APP expression and/or Aβ deposition [200]. Mutations in the PS1 or PS2 genes located on
chromosomes 14 and 1, respectively, enhance the production of Aβ42 [201].
1.2.1.3. Spreading of Tau pathology
It is important to specify that, in AD, Tau pathology starts and spreads through the brain
along a stereotypical pattern that correlates with cognitive decline. This pattern is the
basis of a neuropathological AD staging that defines six neuropathological stages, the so-
called ‘Braak stages’ [202, 203]. Braak stages I and II (or ‘entorhinal stages’) correspond to
the appearance of NFTs in the transentorhinal (medial part of the perirhinal cortex) and
entorhinal cortex and are not associated with clinical dementia. The more pronounced
involvement of both the transentorhinal and entorhinal regions and the formation of NFTs
in CA1 (cornu ammonis 1) of the hippocampus are characteristics of stages III-IV (or
‘limbic stages’). The degree of neuronal damage at stages III-IV may lead to the
appearance of first clinical symptoms. Stages V and VI (or ‘isocortical stages’)
correspond to an abundant spreading of NFTs to isocortical association areas. Patients
with Braak stages V and VI are severely demented, and meet the neuropathological
criteria for the diagnosis of AD (Figure 7).
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Figure 7. Braak stages
Braak stages I and II correspond to the appearance of NFT in the transentorhinal and
entorhinal cortex and are not associated with clinical dementia. Stages III-IV represent
the additional appearance of NFT in the limbic system and may lead to the appearance of
first clinical symptoms. Stages V and VI correspond to an abundant spreading of NFT to
isocortical association areas and patients are severely demented.
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1.2.2. Neurodegenerative tauopathies other than AD
Abundant pathological Tau inclusions in the absence of Aβ deposits characterize a
number of neurodegenerative diseases known as tauopathies. Although they may share
common lesions such as gross brain atrophy, neuronal loss, gliosis, superficial
spongiosis, ballooned neurons, and abnormal glial cells, they show disease-specific Tau
pathology.
Progressive supranuclear palsy
Progressive supranuclear palsy (PSP), or Steele-Richardson-Olszewski disease, is a
multisystem disorder clinically characterized by a parkinsonism component [204].
Cognitive problems, mainly in the form of slowing of thought, may be present as well as
motor disturbances including axial rigidity and vertical gaze palsy [205]. At autopsy,
marked midbrain atrophy with discoloration of the substantia nigra, atrophy of the
superior cerebellar peduncles, subthalamic nucleus and pallidum can be found.
Characteristic Tau inclusions are present in different brain regions as globose-type NFTs
and NTs [206] but also in astrocytes (tuft-shaped astrocytes) and oligodendrocytes (coiled
bodies) (Figure 8).
Corticobasal degeneration
Corticobasal degeneration (CBD) also presents with Parkinsonian features resistant to
dopaminergic drugs, associated with cognitive and behavioural features [205, 207, 208].
Macroscopically, the brain shows asymmetric frontoparietal atrophy and depigmentation
of the substantia nigra. Intracytoplasmic pathological Tau is observed in NTs, pretangle
neurons or small NFTs as well as in astrocytic plaques and oligodendroglial coiled bodies
[209-211] (Figure 8).
Pick’s disease
Pick’s disease (PiD) is a presenile syndrome with a variably progressive clinical course
characterized by aphasic symptoms, language impairment, and behaviour changes [212].
The most distinctive pathological feature is a marked cortical atrophy of the frontal and
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anterior temporal lobes, also known as ‘knife-edge’ atrophy due to severe neuronal loss
and tissue shrinkage in respective brain areas. Argyrophilic (but Gallyas negative) Pick
bodies, first described by Alois Alzheimer [158], are present in neocortical, hippocampal
and subcortical neurons. Abnormally phosphorylated Tau was demonstrated in Pick
bodies and axons [213] (Figure 8).
Argyrophilic grain disease
Argyrophilic grain disease (AgD) is a sporadic late-onset dementia that accounts for
approximately 5% of all cases of dementia. The clinical features of AgD are still poorly
understood, and there might be difficulties to distinguish AgD from AD. A subset of AgD
patients may present clinical features of frontotemporal dementia [214]. Hallmark lesions
of AgD are abundant argyrophilic grains (ArGs) in neuronal processes and coiled bodies
in oligodendrocytes. ArGs are densely distributed through various parts of the limbic area
including the CA1 sector of the hippocampus, layers II and III of the entorhinal and
transentorhinal cortices, the amygdala and the hypothalamic lateral tuberal nuclei (Figure
8). In addition to ArGs, there are abundant pretangle neurons in limbic areas as well as
glial tau pathology, both in astrocytes and oligodendrocytes [215].
Hereditary frontotemporal dementia and parkinsonism due to tau gene mutations
In 1994, a familial form of frontotemporal dementia and parkinsonism was linked to
chromosome 17q21-22 [216]. During the following years other autosomal dominantly
inherited familial forms of frontotemporal dementia were identified that were linked to
the same region. Based on the similarities of the clinical, neuropathological, and genetic
findings, distinct familial cases have been grouped under the umbrella of frontotemporal
dementia and parkinsonism linked to chromosome 17 (FTDP-17) [217]. In 1998, tau gene
mutations (FTDP-17T) were reported in the majority of these families [218-220]. Clinically,
FTDP-17T is characterized by personality changes, motor symptoms and cognitive
decline. The early presenting symptoms are usually disinhibition, loss of initiative,
obsessive-compulsive behavior, and/or psychosis. These changes are followed by
cognitive decline leading to profound dementia. There may be, however, substantial
intra- and interfamilial variation in clinical phenotype [221, 222]. Neuropathologically,
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FTDP-17T presents with severe neuronal loss, astrocytic gliosis, and spongiosis in
cortical and subcortical structures. Filamentous tau inclusions affect both neuronal and
glial cells. Depending on the mutation site, tau aggregates may be composed
predominantly of 3R, 4R or an admixture of 3R and 4R tau isoforms. At present, more
than 40 mutations have been described in 117 families. The mutations in the tau gene,
and the mechanisms by which they impair tau functions and generate filamentous tau
inclusions in FTDP-17T, have recently been reviewed extensively [222-225].
Figure 8. Different types of Tau pathology in tauopathies
Immunohistochemistry with phosphorylation-dependent anti-tau antibody. From left to
right, upper panel: classical neurofibrillary tangles encountered in AD, globose-type
neurofibrillary tangles and tuft-shaped astrocytes in PSP. Lower panel:  Pick bodies in
PiD, astrocytic plaques in CBD, and argyrophilic grains and pretangle neurons in AgD.
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1.2.3. Biochemical heterogeneity among tauopathies
The biochemistry of Tau aggregates specific for the various tauopathies reflects different
Tau profiles differing in isoform phosphorylation and content, thereby allowing a
molecular classification. On SDS gels, phosphorylated Tau migrates more slowly than
non-phosphorylated Tau and, after dephosphorylation, it is possible to characterize the
Tau isoforms associated with specific diseases [54, 226-228]. Four Tau classes have been
established [229] (Figure 9).
The first class (class I) is characterized by a pathological Tau quartet at 60, 64 and 69
kDa with a minor pathological Tau form at 72/74 kDa. This corresponds to the
aggregation of the six different brain Tau isoforms [230, 231], a profile that is typical for AD
and some FTDP-17T forms (Figure 9). Class II corresponds to a triplet of pathological
Tau at 64, 69, and a minor 74 kDa forms, indicative of the aggregation of 4R Tau
isoforms as it occurs in CBD, AgD, PSP, and in some FTDP-17T variants [232, 233] (Figure
9). For the third class (class III), the typical profile corresponds to a triplet of aggregated
Tau at 60, 64, and 69 kDa. This class of tauopathies includes PiD and some FTDP-17T
variants, and comprises tauopathies mainly composed of 3R Tau isoforms (Figure 9).
Class IV tauopathies are represented by a single neurological disorder, myotonic
dystrophy (DM). DM is the most common form of adult-onset muscular dystrophy but is
also a tauopathy since the central nervous system is affected and presents neurofibrillary
lesions such as NFTs [234-236]. The pathological Tau profile of DM is characterized by a
strong pathological Tau band at 60 kDa and, to a lesser extent, pathological Tau bands at
64 and 69 kDa. These DM-associated aggregates are composed of Tau isoforms lacking
N terminal inserts [237] (Figure 9).
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Figure 9. Biochemical classification of tauopathies
Schematic representation of Western blots banding pattern from different tauopathies
before (-) and after dephosphorylation (+). Class I presents nondephosphorylated
aggregated Tau proteins as a major triplet of 69, 64, and 60 kDa and a minor band at 74
kDa that, upon dephosphorylation, correspond to the six Tau isoforms. This profile is
encountered in the brain of patients with AD but also in the case of normal aging (>75
years), dementia pugilistica, Down’s syndrome and some FTDP-17T. Class II groups the
diseases predominantly composed of 4R aggregated Tau isoforms such as corticobasal
degeneration, progressive supranuclear palsy, argyrophilic grain disease and some FTDP-
17T. Pick’s disease and some FTDP-17T are part of the Class III, which consists of
tauopathies with 3R Tau aggregates. Finally, Class IV corresponds to the myotonic
dystrophy that is essentially composed of aggregated Tau isoforms without N-terminal
inserts (0N). (Adapted from Sergeant et al, 2008 [229]).
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1.2.4. Transgenic mouse models of Aβ and Tau pathologies
Establishment of appropriate animal models is not only essential for understanding the
pathogenesis of human diseases but also for the development of potential therapeutic
compounds. This is of particular importance for neurodegenerative disorders, like AD
and tauopathies, as CNS tissue biopsies are not normally performed for diagnostic
reasons precluding analyses of the first pathogenesis steps in human patients. The
generation of transgenic mice has been instrumental for experimentally recapitulating key
pathological features of AD and tauopathies. Many different transgenic models have been
developed so far, selected examples of which will be reported here.
Aβ transgenic mice
The first transgenic mice expressing high levels of the human APP V717F mutation
encountered in FAD were generated in 1995 by Games and colleagues [238]. These mice
develop robust amyloid deposits and neuritic dystrophy. In 1996, transgenic mice
overexpressing the Swedish APP double mutation (KM670/671NL) that leads to a rise in
overall Aβ generation [239, 240], known as the ‘Tg2576’ mouse model, develop Congo red-
positive plaques and age-dependent correlative memory deficits [241]. The well-
characterized APP23 model expresses human APP with the Swedish double mutation at
sevenfold higher levels compared to endogenous mouse APP [242]. Aβ deposition in these
mice starts at around 6 months of age in the cerebral cortex, and dramatically increases
with age to occupy a substantial area of the cerebral cortex and hippocampus in 24-
month-old mice. In these mice, the first amyloid accumulation in leptomeningeal vessels
can be detected 3 months after the first plaques and results in extensive damage to the
vascular smooth muscle layer of CAA-affected vessels [243]. The Aβ deposits in APP23
mice are extracellular and mostly of the compact plaque type. Almost all plaques as well
as the vascular amyloid deposits display Thioflavin S fluorescence and are Congo Red
birefringent in polarized light [242]. Massive astrogliosis can be demonstrated in plaque-
containing brain areas such as neocortex and hippocampus [242, 244]. In close vicinity to
essentially all compact amyloid deposits an accumulation of microglial cells is found [245,
246]. In the hippocampal pyramidal cell layer, a reduction in neuron number adjacent to
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the Aβ deposits is apparent and lower CA1 neuron numbers have been reported for 14-
18-month-old APP23 transgenic mice [247]. Moreover, in these mice, AT8
immunohistochemistry reveals hyperphosphorylated Tau to be exclusively associated
with Congo Red-positive plaques. In addition, APP23 mice exhibit an age-dependent
cognitive decline in visual and spatial learning capacities [248-250].
Tau transgenic mice
The first Tau-transgenic mouse models were generated before the discovery of human
Tau mutations (Table 2). Several Tau-transgenic mice expressing the longest human Tau
isoform were analyzed and led to similar observations: transgenic Tau was found to be
expressed in neurons and, interestingly, phosphorylated at the same sites that are
hyperphosphorylated in human AD brains. However, these mice never developed Tau
filaments, thus defining a ‘pretangle’ phenotype. For instance, ALZ17 mice show
prominent somatodendritic staining for phosphorylated tau in nerve cells from brain and
spinal cord [251]. However, these animals fail to develop Tau aggregates as evidenced by
the absence of tau filaments upon immunoelectron microscopic examination of brain
extracts from 17- 20 month-old mice, and the absence of staining by the Gallyas silver
impregnation technique [127]. In addition, these mice develop axonopathy when they age
and present motor deficits [251].
Mice expressing the shortest Tau isoform were also created and mainly presented the
same pretangle phenotype than the 4R-Tau transgenic mice [252, 253]. However, one of
these models showed, for the first time, a time-dependent assembly of Gallyas-positive
Tau filaments appearing at 12-24 months of age [254]. Transgenic models that are more
relevant to the human condition in terms of Tau pathogenesis were established by
expressing the six Tau isoforms but no Tau filaments were observed [255]. This was
overcome by the generation of a sophisticated mouse model that expressed all six human
Tau isoforms in absence of endogenous murine Tau [256]. By the age of 9 months, these
mice develop Tau filaments affecting neocortical neurons and pyramidal hippocampal
cells, reminiscent of AD [256]. However, neither bona fide NFTs nor significant neuronal
loss occurred in these mice, which highlighted the limitations of wild-type Tau-transgenic
mice in fully reproducing human tauopathy features.
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The discovery of human Tau mutations, pathogenetically linked to FTDP-17T  [222]
triggered the establishment of various transgenic mice in which NFT formation was
recapitulated (Table 3). For instance, missense mutations leading to amino acid
substitutions, such as P301L or P301S, were expressed in mice and resulted in severely
impaired motor phenotypes as well as in neurofibrillary tangle formation. The JNPL3 line
expressing the P301L Tau mutation under the control of the mouse prion promoter
develops motor and behavioural disturbances histologically accompanied by
morphologically heterogeneous tau-positive inclusions resembling those encountered in
human tauopathies [257]. In addition, the fibrillar Tau pathology in these mice can also be
demonstrated at the ultrastructural level. Moreover, the spinal cord pathology observed in
the JNPL3 mice correlates with motor dysfunction. Interestingly, for reasons unknown,
these mice show a gender difference, with higher levels of filamentous Tau pathology
observed in females. Another very similar model is the P301S mouse line that expresses
the transgene under the control of the murine Thy 1.2 promoter [258]. These mice develop
severe paraparesis, mainly attributable to the presence of abundant filamentous inclusions
in the brainstem and spinal cord that consist of phosphorylated Tau. Filaments extracted
from the CNS of these mice resemble the half-twisted ribbons described in cases of
FTDP-17T with a minority being similar to the PHF of AD. Neurodegeneration in the
spinal cord results in an almost 50% loss of motor neurons.
These transgenic animals expressing mutated Tau demonstrate, for instance, the impact
of the P301L and P301S mutations on Tau pathology and provide models in which
potential therapeutic agents can be assessed.
Alternative approaches, e.g. transgenic expression of Tau kinases in mice, are also aimed
at reproducing Tau pathology in vivo. For instance, mice overexpressing P25 or inducible
expression of GSK3-β in animals double transgenic for CamKII and GSK3-β (see
chapter 1.1.3) develop Tau hyperphosphorylation but lack formation of neurofibrillary
pathology [68, 81]. Taken together, these mice, in which potential Tau kinases are
expressed, have reproduced some of the initial features of the Tau pathology observed in
human diseases.
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Table 2: Transgenic mouse strains modeling tauopathy through human wt tau expression
4R Tau important for hippocampal 
development by controlling neuronal 
precursor proliferation and 
differentiation
[74, 85]
Transgene Promoter Histopathology Phenotype Remarks References
MoPrP3R/0N
4R/2N
on murine Tau-null 
background
mThy-1 No obvious pathology; significant increases in 
hippocampal volume and neuronal number
Minor motor phenotype late in life, 
normal mean life span; improved 
cognitive function
Mice fertile and viable Filamentous Tau pathology in 
spatiotemporally relevant distribution
[2]
[29]Relatively low transgene expression, 
pretangle Tau pathology, no NFTs 
No NFT formation [98]
[78]
All six isoforms of human 
Tau, endogenous murine 
Tau background
Human Tau Tau-immunoreactive axonal swellings in spinal 
cord
Same as above, but on 
murine Tau-null 
background
Human Tau Hyperphosphorylated Tau accumulating as PHF
High 3R:4R ratio, no NFT [20
Rare NFT in aged mice (24 months); axonal 
degeneration
Progressive motor deficits [41, 42]
[11]
All 3R isoforms of human 
Tau
mtubulin Tα1 Accumulation of Tau in astrocytes and 
oligodendrocytes with subsequent cell death; 
disruption of myelin sheaths; no neuronal Tau 
lesions
Motor deficits (weakness in hind- 
and forelimbs) associated with age-
dependent accumulation of insoluble 
hyperphosphorylated human Tau
Glial Tau lesions similar to astrocytic 
plaques and oligodendroglial coiled 
bodies in old mice
[34]
3R/0N mHMG-CoA     
reductase 
Progressive motor deficits; unable to 
spread hindlimbs when lifted by the 
tail; neurogenic muscle atrophy, 
normal life span
Pretangle Tau pathology, no NFT 
formation
Pretangle Tau pathology, no NFT 
formation 
[69, 77, 85] mThy-1         
(mThy-1.2 in [69])
Somatodendritic staining for hyperphosporylated 
Tau, early axonopathy with degeneration in brain 
and spinal cord; astrogliosis
4R/2N
4R/2N Human Thy-1 Phosphorylated Tau; somatodendritic Tau 
distribution
4R/2N MoPrP
Axonopathy rescued
Hind-limb abnormality
Weak somatodendritic Tau staining
4R/2N x GSK3ß mThy-1 
Tg Tau expressed in neurons (cell bodies and 
dendrites) and few astrocytes
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Table 3: Transgenic mouse strains modeling tauopathy through human mutant tau expression
Transgene Promoter Histopathology Phenotype Remarks References
P301L (4R/0N) MoPrP Age- and dose-dependent NFT development, 
starting at 4.5 months; neuronal loss, neurogenic 
muscle atrophy
Severe motor and behavioral 
deficits, premature death
NFT pathology linked to neuronal loss [53]
P301L (4R/2N) mThy-1.2 NFT-like, sarkosyl-insoluble, short filament 
structures with hyperphosphorylated tau at 8 
months; gliosis, TUNEL-positive neurons 
Widespread NFTs at 6 months; no axonopathy Late minor motor phenotype, muscle 
and tissue wasting, death prior to age 
of 13 months
[27]
Tau hyperphosphorylation, progressive 
aggregation
[85]
P301L (4R/0N)
(tet-regulatable)
CaMK-II High transgene expression levels in forebrain with 
progressive, age-related NFTs and neuronal loss; 
pretangles starting at 2.5 months
Early cognitive impairment Upon transgene suppression, 
significant improvement of memory 
function, despite ongoing NFT 
accumulation
[70, 72]
P301L (4R/2N) mThy-1
P301L (4R/1N) 2', 3'-CNP Impaired axonal transport before axonal 
degeneration; disruption of myelin and axons 
preceding filamentous oligodendroglial tau 
inclusions 
Weight loss and progressive motor 
weakness, presumably as a 
consequence of neurogenic muscle 
atrophy
P301S (4R/0N) mThy-1.2 Abundant filamentous tau in brain stem and spinal 
cord; significant reduction of spinal cord motor 
neurons with neurogenic muscle atrophy
Severe paraparesis at 5-6 months 
Early synaptic pathology with dysfunction at 6 
months of age, before neuronal loss and NFT 
formation; hippocampal and cortical atrophy by 9-
12 months of age
Limb weakness, progressing to 
paralysis ; median survival 9 months
Oligodendroglial inclusions Gallyas-
positive
[36]
Soluble Tau demonstrated to be 
phosphorylated prior to filament 
assembly; microglia adjacent to Tau-
positive neurons 
[1, 5]
Early prominent microglia activation, 
prior to tangle formation; immuno-
suppression attenuates 
Tau pathology
[97]
G272V (4R/2N)
(tet-regulatable)
MoPrP Transgene expression in neurons and 
oligodendrocytes
No obvious neurological deficits Tau filament formation [30]
P301S (4R/1N) MoPrP
[73]G272V/P301S 
double mutant 
(4R/1N)
mThy-1.2 NFT; pathology starting at 6 months of age in 
hippocampus (CA1) and neocortex; ghost tangles 
at 12 months
Decreased synaptic trans-mission; 
behavioral abnormalities (anxiety, 
cognition, memory); no motor 
deficits
G272V/P301L/R406W 
triple mutant (4R/2N)
mThy-1 High concentration of hyperphosphorylated 
somatodendritic Tau in cortex and hippocampus; 
sarcosyl-insoluble filament formation
V337M (4R/2N) PDGF-ß Degenerating hippocampal neurons, 
immunoreactive for PHF-associated Tau; neuronal 
cell death
Decreased hippocampal neural 
activity, cognitive deficits (elevated 
plus maze)
Tau lesions with advancing age in neuronal 
perikarya
Hindleg weakness in older mice
Lysosomal abnormalities observed in 
forebrain
[54]
[81]
[98]
R406W (4R/2N) CaMK-II Congophilic hyperphosphorylated Tau in forebrain 
at 18 months of age; insoluble Tau filaments in 
aged mice only 
Impaired associative memory (fear 
conditioning), no obvious 
sensorimotor deficit
[82]
R406W (4R/2N) MoPrP
R406W (4R/2N) Syrian hamster PrP Phosphorylated, sarkosyl-insoluble, Gallyas-
positive Tau starting to accumulate in 
hippocampus and amygdala at 6 months of age
In <20% of tg mice, motor 
symptoms and progressive acquired 
memory loss between 10-12 months
APPsw x P301L (4R/0N) MoPrP NFT pathology in limbic system and olfactory 
cortex at 6-9 months of age (enhanced as 
compared to P301L mice); starts at 3 months of 
age in spinal cord and pons
Motor symptoms similar to P301L 
mice [51], with progressive hindlimb 
weakness, hunched posture, eye 
irritations, etc. 
Progressive development of plaque and tangle 
pathology
Synaptic dysfunction prior to onset 
of Aß and Tau pathology
In more than 80% of tg mice, no 
significant behavioral or neuropatho-
logical phenotype; reason for variable 
expression/
penetrance unclear
[40]
APP (and/or Aß) promote NFT 
formation
[52]
[66]
hAPP x Tau +/-
hAPP x Tau -/-
- No changes in hAPP or Aß (soluble or aggregated) 
levels observed
Cognitive deficits of APP mice 
prevented by decreased levels of 
endogenous Tau expression
Study demonstrates link between 
neuronal overexcitation and cognitive 
impairment
[71]
APPsw x PS1M146V x 
P301L
mThy-1.2
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1.2.5. Therapeutic approaches to AD and tauopathies
The development of therapeutic approaches for the treatment of AD is the ultimate goal
of researchers. However, only few compounds with limited efficacy are currently
available.
Symptomatic approach
Currently available therapeutic compounds for AD have shown efficacy in reducing
cognitive symptoms as well as behavioural abnormalities for cases of mild to moderate
AD. They are aimed at reducing the cholinergic deficits [260, 261] or glutamate-mediated
neurotoxicity [262, 263] observed in AD. The four cholinesterase inhibitors approved by the
US Food and Drug Administration (FDA) for the treatment of AD are Donepezil,
rivastigmine, galantamine, and tacrine. Among them, only rivastigmine has been
approved by the European Agency for the Evaluation of Medication (EMEA). Another
drug approved by both FDA and EMEA is memantine, a non-competitive NMDA
receptor, which appears to be protective to neurons [264]. The efficacy of these drugs is
regularly reported in clinical studies but further investigation is needed for the
development of practice guidelines [265-267].
Therapeutic strategies directed against Aβ
According to the Amyloid cascade hypothesis strategies aimed at reducing Aβ production
and/or deposition are promising approaches for the treatment of AD.
In this respect, several studies of active or passive vaccination against Aβ peptide have
been performed pre-clinically. In transgenic mice these efforts have led to a reduction in
Aβ deposition and the prevention of Aβ aggregation, accompanied by functional
improvements [268-273]. Following these promising results, Elan Corporation started a
clinical trial of AD vaccination which had to be stopped in 2002 in phase IIa because
approximately 6% of the treated patients developed meningoencephalitis [274, 275].
However, evidence for efficacy of Aβ immunotherapy has been found in autopsies of
vaccinated patients. Whereas a reduction in the number of Amyloid plaques as well as
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their associated dystrophic neurites and astrocytes has been reported, CAA and NFTs
were not reduced [276-278].
Other therapeutic strategies are aimed at modulating Aβ production by targeting γ-
secretase in order to prevent the formation of amyloidogenic Aβ peptides. A γ-secretase
compound that showed a reduction of Aβ plasma levels has been tested [279]. However,
this strategy can have significant side effects because γ-secretase also cleaves Notch1,
which has important functions in gene regulation [280]. This limitation can be overcome by
the use of certain non-steroidal anti-inflammatory drugs (NSAIDs) that preferentially
reduce the formation of Aβ42 species without affecting Notch cleavage [281]. Aggregation
of Aβ can also be prevented by small molecules that bind to its oligomeric forms. For
instance, tamiprosate, an Aβ antagonist which preferentially binds to soluble Aβ,
interferes with β-sheet formation and has shown successful results [282].
Therapeutic strategies against pathological Tau
Nowadays, targeting abnormal Tau phosphorylation and aggregation is another very
promising strategy. Since hyperphosphorylation of Tau is thought to be a first event in
the formation of fibrillar Tau pathology, interfering with this process might be possible
via targeting potential Tau kinases and phosphatases. In an experimental approach, the
administration of an inhibitor of ERK2 to JNPL3 mice was effective not only at
significantly reducing hyperphosphorylated Tau but also in preventing the typical motor
deficits in these animals [283]. In addition, administration of lithium-chloride, an inhibitor
of GSK-3 activity, resulted in decreased Tau pathology in JNPL3 mice which strongly
correlated with markedly reduced axonal degeneration [284].
Other alternative approaches could be aimed at interfering in the Tau-aggregation
process. Methods for screening Tau aggregation inhibitors have been developed and
some candidate small molecule compounds have been identified [150, 285].
Stabilizing microtubules by agents such as taxols might represent another potential
therapeutic avenue [286]. As such agents act on dividing cells, adverse side effects can
hardly be avoided. Nevertheless, treatment of transgenic mice expressing the shortest
isoform of human wild-type Tau with paclitaxel not only results in the restoration of fast
axonal transport but also leads to the improvement of motor deficits [287].
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Finally, immunization strategies can also be of benefit since a recent study has shown
that active Tau-immunization, in JNPL3 mice, reduces cerebral Tau aggregation and
slows the progression of the behavioural phenotype of these animals [288].
1.2.6. Experimental approaches to model Aβ and Tau pathologies
Protein misfolding and formation of amyloids are common features of the majority of
neurodegenerative disorders, including AD, tauopathies, Parkinson’s disease and
prionoses. It becomes increasingly evident that these cerebral proteopathies share
pathogenic similarities. Understanding the pathological mechanisms might be effective to
establish therapeutic strategies interfering with the proteopathic cascade in AD.
To determine whether Aβ deposition can be induced in vivo brain extracts prepared from
the neocortex of AD patients were unilaterally injected into the hippocampus and
neocortex of 3-month-old APP-transgenic mice (Tg2576) that normally develop Aβ
deposits at the age of 9 months [289]. Analysis of animals 1 month after injection did not
reveal any Aβ deposition. In contrast, 5 months after injection, the injected extract
induced Aβ-immunoreactive senile plaques and vascular deposits in the injected
hippocampus and to a lesser extent in the neocortex. Aβ deposits were only detected in 8-
month-old Tg2576 mice that were injected with AD extracts, but not in age-matched
Tg2576 mice or in Tg2576 mice injected with brain extract prepared from young human
control. There was no evidence of Aβ immunoreactivity in mice sacrificed 5 days, 2
weeks, or 4 weeks after injection with AD extracts, which confirms that the Aβ-
immunoreactivity detected 4 months post-injection did not result from the injectate itself.
A subsequent long-term analysis of this study showed that Aβ deposits were more
numerous in the hemisphere of Tg2576 mice injected with AD extract when compared to
the contralateral (non-injected) side [290]. Hyperphosphorylated Tau was present in the
brain of AD extract-injected Tg2576 mice, especially at sites of intense Aβ
immunoreactivity, whereas no NFTs were detected. Based on these results, the authors
speculated that an abundant nucleating seed was present in the AD brain for the ordered
aggregation of Aβ [290].
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More detailed seeding experiments were performed by intracerebral injection of various
Aβ-containing brain extracts in different Aβ-depositing mouse models [291]. Injection of
AD extract or APP23 brain extract into the brain of male APP23 mice resulted in robust
deposition of Aβ essentially in the hippocampus at 4 months after injection. No Aβ-
deposits were observed in APP23 mice injected with PBS or with extracts prepared from
brains of aged wild-type mice. In addition, the injection of APP23-extract into the brain
of wild-type mice did not produce any Aβ deposition confirming that the Aβ-deposits
observed in APP23-injected animals did not simply represent the injected material.
APP23 brain extracts were also injected into the brain of APP-presenilin-1 (APPxPS1)
double-transgenic mice and vice versa. APPxPS1 mice start to develop Aβ deposits at 3
to 4 months of age, whereas amyloid deposition in APP23 males starts at around 9
months of age [242, 292]. The injection of APPxPS1 extract into the brain of APP23 mice
resulted in a coarse pattern of compact, punctate Aβ deposits whereas the Aβ deposits
induced-by APP23 extracts were more of the diffuse type. When APPxPS1 extract was
injected into APPxPS1 mice, the observed Aβ deposits were even more coarse and
punctate than those observed in APP23 hosts whereas the injection of APP23 extract into
APPxPS1 mice resulted in a mixture of both diffuse and compact Aβ deposits. In
addition, the first Aβ deposits in APPxPS1 animals were observed as soon as 1 month
post-injection with Aβ-containing extracts whereas no deposits were detected before 2
months after injection in APP23 mice. Injection of Aβ extracts that were either Aβ-
immunodepleted or treated with formic acid did not induce Aβ deposition suggesting that
the seeding agent consisted of an aggregated Aβ species. This study demonstrated that
both, agent and host are critical for in vivo Aβ seeding.
This experimental approach was also useful to assess the relationship between Aβ and
Tau pathologies in AD. This was first addressed by using non-transgenic species such as
monkeys and rats [293]. Intracerebral injection of fibrillar but not of soluble Aβ induced
neuronal loss, Tau phosphorylation, and microglial activation in the cerebral cortex of
rhesus monkeys. This observation was age- and species-specific, since the same Aβ
preparations were not toxic in young monkeys or in rats of different ages [293]. Similar
approaches were used in transgenic mice to directly manipulate the interaction between
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Aβ and Tau. The injection of synthetic preparations of fibrillar Aβ42 in Tau-transgenic
mice (P301L) resulted in a five-fold increase of NFTs in the amygdala of transgenic mice
from where neurons project to the injection sites [294]. In this study, the induction of NFTs
was observed as early as 18 days after Aβ42 injection. NFTs were identified by Gallyas
staining as well as by the conformation-specific antibody AT100 and were composed of
twisted filaments. Another breeding approach validated these observations by mating
APP (Tg2576) and Tau (P301L) transgenic mice [295]. These double-transgenic mice
developed a more than sevenfold increase in NFT numbers in various regions of the
brain, whereas plaque numbers were unchanged [295]. Altogether, these experiments
demonstrate pathogenic interactions between Aβ and Tau and seem to confirm the Aβ
cascade hypothesis. However, they still fail to reproduce sporadic AD since wild-type
human Tau was not influenced by Aβ pathology. In addition, they do not address the
pathogenesis of ‘pure’ tauopathies.
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ABSTRACT
AIMS: In this study we aimed to investigate the interaction between amyloid- and Tau-
associated pathologies to gain further insights into the development of Alzheimer’s
disease. We examined the formation of neurofibillary tangles (NFT) in adult mouse brain
without the prior overexpression of Tau at embryonic or early post-natal stages to
dissociate any developmental mechanisms. METHODS: Lentivirus technology was used
to examine the effects of overexpressing mutant Tau-P301S in the adult mouse brains of
both wild-type and amyloid precursor-protein (APP)-transgenic mice. RESULTS: We
find that injection of lentivirus Tau-P301S into the hippocampus of adult wild-type mice
increases levels of hyperphosphorylated Tau, as early as 3 months post injection.
However, no NFT are found even after 13 months of Tau expression. In contrast, the
overexpression of Tau-P301S in adult APP-transgenic animals results in the formation of
Gallyas stained NFT. CONCLUSIONS: Our current findings are the first to show that
overexpression of Tau-P301S in adult mice overexpressing APP, but not wild-type mice,
leads to enhanced Tau-related pathology.
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INTRODUCTION
Tau is a microtubule-associated protein that polymerizes tubulin and is involved in
intracellular trafficking [1-2]. This protein is located in axons under normal conditions but
is hyperphosphorylated and found in cell bodies and dendrites in various Tauopathies
including Alzheimer’s disease (AD). Neurofibillary tangles (NFT) are composed of
filaments of hyperphosphorylated Tau and the temporospatial spreading of NFT in AD
correlates well with the cognitive decline [3]. In addition, mutations in the Tau gene are
associated with a subset of frontotemporal dementias with parkinsonism linked to
chromosome 17 (FTDP-17T) [4-6].
A number of Tau transgenic mouse models show that overexpression of wild-type
Tau results in higher levels of its hyperphosphorylated form (so called the pretangle
stage) as seen in human Tauopathies [7], but no or limited formation of NFT [8-12]. In
contrast, robust NFT pathology develops in transgenic mice expressing a FTDP-17T
linked P301L Tau mutant [13-14]. Additionally, abundant filaments made of
hyperphosphorylated Tau can be observed in transgenic mice expressing the FTDP-17T
linked P301S Tau mutant [15]. NFT are also found in transgenic mice overexpressing
V337M Tau [16] and R406W Tau [17].  Not surprisingly, transgenic mice with double
mutations in Tau (G272V, P301S) [18] or triple mutations (G272V, P301L, R406W) [19]
also display NFT formation.
In AD pathogenesis, the ‘Amyloid cascade hypothesis’ holds that accumulation of
Amyloid-β-peptide in the brain is an early and critical event that triggers a cascade of
events leading to hyperphosphorylation and somatodendritic segregation of Tau, and
formation of NFT [20]. To examine the interaction between Amyloid- and Tau-associated
pathologies, two approaches have been used: (i) Amyloid precursor protein (APP)-
transgenic animals have been mated with Tau-transgenic mice [21-23] and (ii) seeding
studies with injected Aβ-containing preparations into Tau transgenic animals [21, 24].
Collectively these studies indicate that Tau-related pathology is augmented in the
presence of abnormal levels of Aβ. Although conditional Tau transgenic animals exist,
they have not been crossed with APP transgenics or used in seeding studies. These mice
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express Tau P301L at an early age starting at P7 and develop NFT [25-26]. Discontinuing
Tau expression in these mice in adult stages results in stabilisation of neuronal numbers
and recovery of memory function but, surprisingly, NFT continue to accumulate [25].
To our knowledge, there has been no study that examines the effects of Aβ and/or
APP on the formation of NFT without the overexpression of Tau at the embryonic or
early postnatal stage. To dissociate any effects of Tau overexpression during
development, we examined the effects of overexpressing Tau-P301S (a FTDP-17T linked
mutant) starting at a much later age in adult brains of wild-type and APP-transgenic
animals by starting expression at 6 months of age using lentivirus technology.
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RESULTS
Distribution of lentivirus-mediated transgene expression – To determine the
distribution of protein expression mediated by lentivirus in mouse brain, the expression
of an EGFP transgene was evaluated under the control of the PGK promoter (LV-EGFP).
When the LV-EGFP was delivered into the hippocampus, EGFP expression spread over a
region of approximately 5 mm cubic area (Figure 1A). At the cellular level, EGFP
expression occurred in cell bodies of pyramidal layers and the dentate gyrus as well as
axons and dendrites (Figure 1A). On comparison, the injection of LV-EGFP into the
corpus callosum gave a more extensive distribution which is likely explained by a spread
of EGFP throughout the fibre tracts of the corpus callosum (Figure 1B). When injected
into the corpus callosum, expression also reached adjacent cortical cells and the
pyramidal cells of hippocampal subfield CA1 (Figure 1B). The EGFP expression was
additionally found in the ventricular linings, most probably the ependymal cells, when
injected into the corpus callosum (Figure 1B).
The LV-hTauP301S drives stable expression of Tau in neuronal cultures and in
the hippocampus – Lentivirus-mediated expression of the human TauP301S (LV-
hTauP301S) was driven by the PGK promoter, similar to LV-EGFP. The LV-hTauP301S
was first tested for its ability to drive expression in vitro.  CHO cells transduced with LV-
hTauP301S stained positively with an anti-Tau T5 antibody 72h post-transduction
(Figure 2A). In addition, rat cortical cultures (E18) transduced at DIV 7 with LV-
hTauP301S showed immunoreactivity with a human specific anti-Tau T14 antibody at
48h (data not shown) and 96 hours post-transduction (Figure 2B). Furthermore, Western
blot analysis of rat cortical cultures transduced with LV-hTauP301S showed expression
of hTauP301S, where the expression level correlated with the amount of lentivirus used
for transduction (Figure 2C).
The LV-hTauP301S was injected unilaterally into the hippocampus of wild-type mice
and expression level of total hTauP301S was detected in lysates prepared from each
isolated hippocampus by Western blotting using N-Tau5 (total Tau) and HT7 (human
specific) antibodies (Figure 3). Hippocampi, injected and non-injected side, from the
66
same animals were used as positive and negative controls, respectively. There was an
increase in total Tau expression as detected by the N-Tau5 antibody in the injected
hippocampi as compared with the non-injected hippocampi. Accordingly, there was a
dramatic increase in HT7 immunoreactivity in lysates prepared from injected hippocampi
compared with non-injected, indicating the overexpression of hTauP301S. The
expression of hyperphosphorylated Tau was also determined using the AT8 antibody
(Figure 3). Levels of hyperphosphorylated Tau were markedly augmented in LV-
hTauP301S injected side compared to non-injected side controls. The expression of
hTauP301S remained strong as detected by all three antibodies until thirteen months post-
injection compared to non-injected side controls (Figure 3).
Notably, the T14 and HT7 (human specific) antibodies showed weak
immunoreactivity in non-infected neuronal cultures (Figure 2) and non-injected
hippocampi (Figure 3), respectively. In the neuronal cultures, the non-transfected and
transfected cells were prepared in different wells; the weak staining found in the non-
transfected samples is likely due to cross-reactivity of the T14 antibody with rodent Tau
(Figure 2). There is a possibility that the weak immunoreactivity found in non-injected
hippocampal samples using the HT7 antibody was due to the partial spread of the virus in
the mouse brain to the non-injected hippocampus (Figure 3). In light of the finding that
all three N-Tau5, HT7 and AT8 antibodies showed increased immunoreactive bands in
the LV-hTauP301S injected side, the increased immunoreactivity is likely a consequence
of Tau overexpression and a subsequent increase in phosphorylated Tau levels, compared
with the non-injected side.
Overexpression of hTauP301S in adult APP-transgenic mice promotes tangle
formation – Histological analysis using the T14 antibody was performed to examine
distribution of total hTauP301S expression after injection of LV-hTauP301S in wild-type
animals (Figure 4A). Total hTauP301S expression started to appear at 2 months post
injection and increased, remaining strong at 7 months (not shown) and 13 months post
injection (Figure 4A). Injection of the LV-hTauP301S towards the CA3 region of the
hippocampus resulted in the expression of hTauP301S predominantly in the CA3 subfield
of the hippocampus and on occasion in the dentate gyrus (Figure 4A). The hTauP301S
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expression was found in cell bodies and axonal tracts of the mossy fibres in the dentate
gyrus. The AT8 antibody was used to determine the distribution of hyperphosphorylated
Tau (Figure 4B). Few neurons expressing hyperphosphorylated Tau were found at 2
months post injection, which was abundant at 7 months (not shown) and also 13 months
(Figure 4B). Hyperphosphorylated Tau was found predominantly in the areas of high
total hTauP301S expression, mainly in the CA3 region. These data were in agreement
with Western blotting results (Figure 3) showing that the number of neurons expressing
hyperphosphorylated Tau was proportional to those expressing total hTauP301S levels.
To determine synergy between Aβ deposition and hyperphosphorylation or
aggregation of Tau, the LV-TauP301S was injected into APP23-transgenic mice, which
overexpresses human APP751 with the Swedish double mutation (K670N/M671L) under
the control of a neuron-specific Thy-1 promoter [31]. Animals were injected with LV-
hTauP301S (and with LV-EGFP for control groups) before onset of plaques at 6 months
of age and examined 13 months post-injection, where plaque pathology was evident. The
extent of Aβ deposition was examined using an antibody specific for Aβ40 (NT12
antibody). Plaques were detected mainly in the cortical area of APP23 mice whereas no
staining was observed in the brain of wild-type animals (not shown). The expression and
distribution of total human TauP301S (T14 antibody) was similar in wild-type (Figure
4A) and APP23 (Figure 4D) mice injected with LV-TauP301S, but more intense
cytoplasmic AT8 staining was observed in APP23 mice (Figure 4E) when compared with
wild-type animals (Figure 4B). No or very few NFT were detected using the Gallyas
staining in wild-type animals injected with LV-TauP301S, suggesting that Tau pathology
in these mice remained in a ‘pretangle stage’ (Figure 4C). In contrast, APP23 transgenic
mice injected with LV-TauP301S revealed a high number of Gallyas positive cells
indicating that formation of NFT is augmented in animals overexpressing APP (Figure
4F). No difference was found in the number of plaques in the hippocampus of APP23
transgenic mice injected with LV-TauP301S compared with those injected with LV-
EGFP, indicating that expression of mutated Tau does not influence Aβ deposition (not
shown).
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DISCUSSION
To our knowledge, this is the first report showing that the overexpression of Tau starting
in adult mouse brain leads to the formation of NFT in APP-transgenic mice but not wild-
type mice. The development of NFT was seen at 13 months after expression of LV-
TauP301S, occurring at a later age than other mouse models expressing mutated forms of
Tau [13-19], possibly due to differences in expression levels and/or the fact that we avoid
expression of Tau at embryonic or early post-natal stages, which may increase the rate
development of NFT. The findings also show that directed overexpression of TauP301S
can result in the development of tangles in the CA3 region of the hippocampus. These
results are in agreement with previous reports, confirming that while APP and/or Aβ
augments Tau pathology, the overexpression of Tau has little impact on plaque
pathology.
The first Tau transgenic models that overexpressed wild-type Tau showed limited or
no NFT pathology despite an elevated level of hyperphosphorylation of Tau, reminiscent
of a ‘pretangle’ phenotype [8-12]. In contrast, a number of transgenic animals that
overexpress pathogenic Tau mutants have been shown to develop NFT pathology. Two
sets of studies, namely, the direct injection of Aβ fibrils and the overexpression of APP,
support the notion that Aβ and/or APP can increase NFT formation. In particular, the
injection of fibrillar Aβ42 into the cortex and the CA1 region of the hippocampus
increases phosphorylation of Tau and the formation of NFT in P301L mice but not mice
expressing wild-type Tau; the NFT are found in cell bodies of the amygdala, where the
injected neurons are known to project [24]. To examine the interaction of amyloid- and
Tau-associated pathologies, APP transgenic animals (Tg2576 mice) have been mated
with Tau P301L-transgenic mice (JNPL3 mice) [22]. These double-transgenic animals
(TAPP mice) develop both plaques and tangles and show that Tau overexpression has no
effect on amyloid pathology while APP overexpression enhances NFT formation [22], in
agreement with our findings. In TAPP mice, NFT develop by around 6 months of age at
an increased number compared with P301L single-transgenic mice [22]. In a triple-
transgenic model, the 3xTg-AD mice harbour mutations of APP (Swedish), presenilin
PS1 (M146V), and Tau (P301L) and develop plaques in the neocortex at 3 months of age
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and in the hippocampus by 6 months. NFT appear in the hippocampus at 12 months, then
spread to the cortex [23]. In this mouse model, Aβ immunotherapy reduces extracellular
Aβ plaques and intracellular Tau pathology. Tau clearance is thought to be mediated by
the proteasome and to be dependent on the phosphorylation state of Tau;
hyperphosphorylated Tau aggregates are unaffected by Aβ antibody treatment [35]. The
regulation of Tau pathology by amyloid is in agreement with our current findings.
In summary therefore, a number of studies have shown that Tau expression (mutant
forms) leads to NFT formation and that amyloid pathology increases the levels of NFT.
These studies have used mainly transgenic animals where APP and/or Tau are expressed
at ontogeny. In the current study we have shown the overexpression of mutant Tau
(P301S) in the brains of adult transgenic mice overexpressing APP (but not wild-type
mice) leads to NFT formation. Our studies support the notion that APP and/or Aβ can
promote Tau-related pathology even in the adult brain, indicating that amyloid-induced
NFT formation can be independent of embryonic and/or post-natal developmental
mechanisms.
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MATERIALS AND METHODS
Lentiviral vector and virus preparation – The vector was constructed based on the
backbone of pLL3.7 [27] using standard molecular-cloning techniques. The
cytomegalovirus (CMV) promoter was replaced by phospho-glycerate-kinase (PGK)
promoter (obtained by polymerase chain reaction amplification of the PGK promoter
from pSIREN-Retro Q vector) (BD biosciences, NJ, USA) generating the enhanced green
fluorescent protein (EGFP) pLL4.0-PKG lentiviral (LV) transfer vector. The cDNA
encoding the isoform (4R0N) [28] of the human Tau mutant P301S was then cloned into
the pLL4.0-PGK vector (LV-hTauP301S) by replacing the EGFP with hTauP301S. The
viral particles were produced as described previously for both LV-hTauP301S and LV-
EGFP [29]. The viral suspension was concentrated by ultracentrifugation and re-suspended
in phosphate buffer saline (PBS) with 2 % bovine serum albumin.
Analysis of Tau expression in cell cultures – Chinese hamster ovary (CHO) cells were
cultured in HAM F12 media supplemented with 10% foetal calf serum and 1% penicillin
and streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were plated on glass coverslips
in 12-well plates at 1.5x105 cells per ml. Two days after, transduction was performed with
LV-hTauP301S using one transfecting particle per cell. Three days post transduction, the
cells were fixed in 4% paraformaldehyde in PBS (PFA), permeabilized in 0.2% Triton X-
100 (TX-100) followed by incubation in blocking buffer (2% BSA and 5% goat serum in
PBS) for 2h at room temperature before addition of primary antibody. Anti-Tau (Tau-5)
antibody (Abcam, Cambridge, UK) was used (1:2000) for human Tau detection. Alexa
fluor 488 anti-mouse (1:1000) (Molecular Probes, Invitrogen, CA, USA) was used as
secondary antibody. Coverslips were mounted with Vectashield mounting media and
pictures taken with an ORCA-AG CCD camera (Hamamatsu, Massy, France). Neuronal
cortical cultures were prepared from embryonic day 18 Sprague Dawley rats as
previously described [30]. The cortices were dissected in cold Hank’s buffered salt
solution (Invitrogen), and dissociated using trypsin for 10 min at 37°C. Cultures were
plated onto poly-D lysine culture dishes (BD biosciences) or chamber slides (BD
biosciences) and maintained at 37°C, 5% CO2 in Neurobasal media (Invitrogen) with B27
supplement (Invitrogen). The neuronal cultures were transfected after 7 days in vitro
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(DIV) and immunocytochemistry was performed 2-3 days after addition of lentivirus as
described for CHO cells.
Stereotaxic Injection – Lentiviruses (either LV-EGFP or LV-hTauP301S) were
stereotaxically injected into the right hippocampus of adult male C57Bl/6 mice (Charles
River Laboratories, l’Arbresle, France), APP23-transgenic animals and wild-type
littermates of 6 months of age [31]. Viral suspensions (1 µl volume) were injected with a
10 µl Hamilton syringe at a speed of 0.4 µl / min with an automatic injector (Stoelting,
Wood Dale, IL, USA), and the needle was left in place for an additional 5 min before
being withdrawn. Stereotaxic injections were delivered within the hippocampus with the
following coordinates in millimeters: posterior, 1.75; lateral, 1.5; and ventral, 2.3. The
posterior and lateral coordinates were calculated from the Bregma and the ventral
coordinates were calculated from the skull surface. Animal studies were conducted in
accordance with Swiss animal welfare authorities.
Histology – At the time points indicated post injection of lentivirus, animals were
anaesthetized with sodium pentobarbital and transcardially perfused with saline and 4%
PFA. Brains were removed, kept overnight at 4°C in 4% PFA and paraffin-embedded
(Medite TPC 15 Duo, Nunningen, Switzerland). Sections of five microns were made with
a microtome (Microm HM 340, Volketswil, Switzerland) and placed onto Superfrost
glass slides (Menzel Gläser, Braunschweig, Germany). Sections were rehydrated and
additionally heated at 90°C for 10-30 min in citrate buffer (Zymed, Invitrogen, Carlsbad,
CA, USA) for epitope retrieval for T14 and AT8 antibodies. Permeabilization was
performed in 0.2% TX-100 followed by incubation in blocking buffer (2% BSA and 5%
horse serum in PBS) for two hours at room temperature before addition of primary
antibodies. Primary antibodies to detect Tau expression were anti-human Tau T14 clone
(1:1000) (Zymed) and anti-phosphorylated Tau AT8 (1:1000) (Pierce, Rockford, IL,
USA) and to detect EGFP expression was anti-EGFP (1:1000) (Molecular Probes).
Secondary antibody anti-mouse IgG conjugated to biotin (1:200) (Vector) was applied 1
hour at room temperature. Sections were stained with ABC kit (Vector) and AEC (Sigma,
St Louis, MO, USA) following manufacturer instructions. Additional haematoxylin
staining was performed to visualize nuclei and general morphology. After mounting
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(Vectamount, Vector), sections were visualized with Zeiss microscope. Gallyas silver
technique, which detects most NFT in human Tauopathies [32-34] was used to detect NFT
in injected mouse brains.
Analysis of Tau expression in hippocampal samples – Thirteen months post-injection
of lentivirus, mice were anaesthetized with sodium pentobarbital and decapitated. Brains
were removed, left and right hippocampi were separately isolated and homogenized on
ice. Lysis buffer containing 50 mM Tris, 150mM NaCl, 1% TX-100, 10% Glycerin,
protease (Roche, Mannheim, Germany) and phosphatase inhibitor cocktails (Calbiochem,
Merk, Nottingam, UK) was added at a ratio of 100 mg tissue/ml buffer and the
homogenates were sonicated repeatedly at maximum 50 Watts. After 1h rotation on a
wheel at 4°C, the total homogenates were aliquoted and stored at -80°C until used for
Western blotting.
Western blotting – Chinease hamster ovary, neuronal cultures and hippocampal samples
were run on NuPAGE 7% or 4-20% Tris-Acetate pre-cast gels (Invitrogen), transferred
onto PVDF membrane (Invitrogen) and blocked with 5% non-fat milk powder in Tris-
Buffered Saline supplemented with 0.05% Tween-20 (TBST). Membranes were then
incubated overnight at 4°C with primary antibodies in 2.5% non-fat milk powder in
TBST. Following washing in TBST, membranes were incubated for 1 hour in 2.5% non-
fat milk powder in TBST with horseradish peroxidase (HRP)-conjugated secondary
antibodies. When required, blots were stripped using Restore Western Blot Buffer
(Pierce). The primary antibodies were: rabbit polyclonal anti-total Tau, N-Tau5 (1:2000;
in-house antibody raised against a Tau peptide, amino acids 1-16) [35], mouse monoclonal
anti-human Tau clone HT7 (1:1000; Innogenetics, Gent, Belgium), mouse monoclonal
anti-phospho Tau clone AT8 (1:1000; Pierce); anti-human Tau T14 clone (1:1000;
Zymed) and mouse monoclonal anti-βTubulin isotype III clone SDL.3D10 (1:2000;
Sigma). The secondary antibodies were: goat anti-rabbit IgG (Sigma) and goat anti-
mouse IgG (Sigma). Supersignal West Femto (Pierce) was used for HRP detection on
Hyperfilm ECL (Amersham, Bucking-hamshire, UK).
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FIGURE LEGENDS
Figure 1. PGK-EGFP lentivirus expression in mouse brain. Wild-type B6 mice were
injected with 2µl lentivirus expressing EGFP under PGK promoter into the hippocampus.
After two weeks, the animals were perfused with 4% PFA . 50 micron sections were
analysed for EGFP expression by immunostaining using the EGFP antibody. (A) Above,
strong EGFP signal was observed in the injected side of the hippocampus. Below, higher
magnification of the hippocampus (just to precise) (B) Lentivirus was injected in the
Corpus callosum showing a large spreading along the fibres tracts and some pyramidal
neurons of CA1 as well as ependymal cells of the ventricles. Cortex (c), corpus callosum
(cc), CA1/3 field of hippocampus (ca1/3), hippocampus (h), dentate gyrus (dg), ventricle
(v), 2.5x and 5x magnification.
Figure 2. Lentivirus-hTauP301S mediates stable expression of Tau in cell cultures. (A)
CHO cells were infected with lentivirus TauP301S for 48 hours, fixed and incubated with
anti-Tau (T5) antibody. No endogenous Tau was detected in non-infected CHO cells
while detectable expression was found in the infected cells. (B) Same transduction
procedure was applied on primary cortical cultures incubated with anti-human Tau (T14)
antibody. (C) Primary cortical culture lysates were analysed on Western blot with anti-
human Tau (T14) antibody. Expression levels were proportional to the amount of
transducing particles used. The amount of LV-hTauP301S used for transfection is
indicated, none (non-transfected), 2 µl and 4 µl.
Figure 3. Lentivirus-hTauP301S mediates stable expression of Tau in the hippocampus.
Hippocampi of wt mice were dissected 13 months post-injection and lysates of injected
and non-injected side analysed by Western blot. Tau protein expression was measured
with N-Tau5 that detects total Tau, HT7 for human Tau detection and AT8 for human
hyperphosphorylated Tau. H1 and H2 are hippocampus from two different mice. Beta-
tubulin showed equal protein amounts loaded.
Figure 4. Expression of Tau P301S in APP23 mice drives tangles formation. Images are
from wild-type or APP23 mice sacrificed 13 months after injection with lentivirus
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hTauP301S. T14 immunostaining (1:1000; x 100 magnification) showed the expression
of human Tau P310S in the hippocampus of wild-type (a) and APP23 (d) mice.
Hyperphosphorylated Tau was detected using the AT8 antibody (1:1000; x 100
magnification) in both wild-type (b) and APP23 (e) animals. Inserts in b and e (x630)
show high magnification of AT8 positive neurons in the CA3 region of the hippocampus.
Note that more intense cytoplasmic AT8 staining in the APP23 animal. Numerous
Gallyas staining (x400 magnification, CA3 region of the hippocampus) neurofibrillary
tangles were found in the APP23 (c) but not in the wild-type (f) mice. The figures shown
are representatives of 5-6 animals for each condition.
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ABSTRACT
Alzheimer’s disease presents morphologically with senile plaques, primarily made of
extracellular amyloid-β  (Aβ) deposits, and neurofibrillary lesions, which consist of
intracellular aggregates of hyperphosphorylated tau protein. To study the in vivo
induction of tau pathology, dilute brain extract from aged Aβ-depositing APP23
transgenic mice were intracerebrally infused in young B6/P301L tau transgenic mice. Six
months after the infusion, tau pathology was induced in the injected hippocampus but
also in brain regions well beyond the injection sites such as the entorhinal cortex and
amygdala, areas with neuronal projection to the injection site. No or only modest tau
induction was observed when brain extracts from aged non-transgenic control mice and
aged tau-depositing B6/P301L-transgenic mice were infused. To further study Aβ-
induced tau lesions B6/P301L tau transgenic mice were crossed with APP23 mice.
Although Aβ deposition in double-transgenic mice did not differ from single APP23-
transgenic mice, double-transgenic mice revealed increased tau pathology compared to
single B6/P301L tau-transgenic mice predominately in areas with high Aβ plaque load.
The present results suggest that both extract-derived Aβ species and deposited fibrillary
Aβ can induce the formation of neurofibrillary pathology. The observation that infused
Aβ can trigger the tau pathology in the absence of Aβ deposits provides an explanation
for the discrepancy between the neuroanatomical location of Aβ deposits and the
development and spreading of tau lesions in Alzheimer’s disease brain.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder that is pathologically
characterized by senile plaques, primarily composed of extracellular deposits of amyloid-
β (Aβ) peptide, and neurofibrillary tangles, composed of intracellular aggregates of
hyperphosphorylated tau protein [1]. The amyloid cascade hypothesis of AD pathogenesis
holds that accumulation of polymerised forms of Aβ in the brain is an early and critical
event that triggers a cascade of events leading to hyperphosphorylation and
somatodendritic segregation of tau and formation of neurofibrillary tangles [2]. Consistent
with this view, previous in vivo studies have revealed an interaction between Aβ and tau
pathology in vulnerable brain regions [3-5].
Previously we have shown that intracerebral injection of dilute Aβ-containing human and
murine brain extracts induces cerebral amyloidosis in young, predepositing amyloid
precursor protein (APP23) transgenic mice [6]. In the present study we examined whether
the same Aβ-containing brain extracts would also induce tau pathology in young
B6/P301L mutated tau-transgenic mice and thus confirm and expand previous studies in
which synthetic Aβ was intracerebrally infused in tau transgenic mice [4]. However, in
contrast to this latter study in which a high concentration of fibrillary synthetic Aβ was
injected and gave rise to amyloid deposits in the host at the injection site, the Aβ in the
brain extract was at low concentration and did not form amyloid deposits in the injected
host [6]. To complement this exogenous induction of tau pathology, we also crossbred
B6/P301L tau transgenic mice with APP23 transgenic mice to study the induction of tau
pathology by (genetic) expression of APP/Aβ. A similar cross breeding strategy has
previously been reported to induce tau pathology in selected brain regions [3]. Our results
suggest that both the infusion of an Aβ-containing extract and the deposition of fibrillary
Aβ can induce the formation of neurofibrillary pathology.
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RESULTS
Tau pathology in P301L tau transgenic mice on C57BL/6J background − On a mixed
C57BL/DBA2/SW background, heterozygous P301L transgenic female mice develop tau
pathology between 7 to 11 months of age, whereas disease onset in males is between 11
to 15 months [3,7]. To minimize immunological consequences and to minimize genetic
variability in brain extract infusion studies and cross-breeding (see below), P301L
transgenic mice were backcrossed to a C57BL/6J genetic background for at least seven
times (thereafter termed B6/P301L mice; see Materials and Methods). Surprisingly,
B6/P301L mice revealed a substantial delay in the development of tau pathology
compared to the original P301L mice.
In female B6/P301L mice intracellular tau deposition (assessed with phosphorylation-
dependent AT8 antibody) was not apparent in a group of 11- to 12-month-old mice (mean
age 11.5 ± 0.3 month; n=5; indicated is the SEM) (Figure 1, A-E). At ~ 18 months of age,
female B6/P301L mice became symptomatic and were unable to spread their hindlimbs
when lifted by the tail. Within 1 to 3 months of disease onset, mice showed weight loss,
and there were signs of dystonic posture. At that stage another group of mice (mean age,
19.8 ± 0.6 months; n = 6) was sacrificed and analyzed. Neuropathologically, similar to
the original report of P301L mice on the mixed background [7], a substantial amount of
hyperphosphorylated tau protein accumulated in affected neurons of the spinal cord, brain
stem nuclei, and also of the hippocampus, entorhinal cortex, and amygdala (Figure 1, F-
J). In the spinal cord, amygdala and brain stem (Figure 1, I, J), the majority (~ 80 to 90%)
of these tau lesions were Gallyas-positive similar to neurofibrillary tangles found in AD
brain. These changes were followed by axonal degeneration in descending fibre tracts of
the spinal cord and by neurogenic atrophy in skeletal muscles (not shown), all overall
similar as described previously in P301L mice on a mixed genetic background [7].
Male heterozygous B6/P301L mice did not show any clinical symptoms up to 30 months
of age. Consistently, a group of 27 month-old B6/P301L mice (26.5 ± 1.1 months; n = 6)
revealed only little tau pathology in the spinal cord and brain stem with no signs of tau
lesions in other areas of the brain.
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Characterization of murine brain extracts − Brain homogenates were prepared from
the neocortex of aged, Aβ-depositing APP23 mice and an aged-matched non-transgenic
control littermate (Figure 2A and B). Western blotting of the APP23 brain extract
revealed Aβ levels of ~ 1 to 10 ng/µl with more Aβ1-40 compared to Aβ1-42 (Figure
2D) consistent with previous findings [6,9]. As an additional control, an extract from the
brain stem and diencephalon of an aged B6/P301L transgenic mouse was used. The
presence of tau lesions and of the shortest 4-repeat human tau isoform was demonstrated
by immunohistochemistry and Western blotting (Figure 2, C and D).
Intracerebral injection of Aβ-containing brain extract induces tau pathology in
B6/P301L tau transgenic mice − Extracts were unilaterally injected into the right
hippocampus and overlying somatosensory cortex of young (5- to 6-month-old)
heterozygous B6/P301L female mice. All mice were analyzed 6 months later, ie, when
host mice were 11 to 12 months of age. At that age, uninjected B6/P301L female mice
have not yet developed significant tau pathology (see Figure 1, A-E).
Intracerebral injection of the Aβ-rich APP23 extract induced robust deposition of tau
throughout the injected hippocampus (assessed by phosphorylation-dependent AT8
antibody; Figure 3, A and B). In contrast injection of non-transgenic brain extract or PBS
did not induce any tau lesions (Figure 3, C and E). Modest tau pathology was also
induced with the B6/P301L extract, but this was not statistically significant (Figure 3 D
and Figure 4A). APP23 extracts injected into non-transgenic mice did not induce any tau
deposits (Figure 3F), indicating that the expression of human tau was necessary for the
induction of tau lesions by the Aβ-containing extracts. All these observations were
supported by quantitative analysis (Figure 4A).
No tau lesions were observed around the injection site of the neocortex. Tau pathology,
however, was induced in brain regions farther away from the injection sites, such as the
entorhinal cortex and the amygdala, but not brain stem (Figure 3A; Figure 4, B-E). In
most regions tau induction appeared confined to the injected hemisphere. However, in the
amygdala the induction, albeit to a lesser degree, also occurred contralateral to the
injection site (Figure 4C).
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Immunostaining for Aβ at any time after the infusion of the Aβ-containing extracts did
not reveal any Aβ deposition (data not shown), consistent with previous studies [6].
Gliosis was limited to the needle track and was similar among all mice independent
whether of they were injected with PBS or brain extracts.
Increased tau pathology in double APP23 x B6/P301L tau transgenic mice −
B6/P301L tau transgenic mice were crossed with APP23 transgenic mice. Before Aβ
deposition, double-transgenic B6/P301L x APP23 mice did not exhibit increased tau
pathology compared to the single transgenic B6/P301L littermate control mice (results
not shown). However, at the time of significant amyloid deposition, a robust increase of
tau pathology (assessed by phosphorylation-dependent AT8 antibody) in the entorhinal
cortex, hippocampus, and to a lower extent in the amygdala but not in brain stem regions
was noted in the double transgenic B6/P301L x APP23 mice compared to the single
transgenic B6/P301L control mice. This was true for the female double-transgenic mice
(21.6 ± 0.9 months old; data not shown) and particularly appreciable in male double-
transgenic mice (27.6 ± 0.7 months old; Figure 5A) since single-transgenic male
B6/P301L tau mice do not develop tau pathology up to this age (Figure 5B). In the
entorhinal cortex and hippocampus, a subset (~ 50 %) of these induced tau lesions was
Gallyas-positive (Figure 5I). Stereological analysis of the amyloid load did not reveal any
differences between double B6/P301L x APP23 and single-transgenic APP23 male mice.
Notably, however, there was a great region-specific variability of amyloid deposition
with neocortex and hippocampus revealing the highest amyloid load, followed by the
amygdala and the brain stem, with the latter showing virtually no amyloid deposition
(Figure 5D). Tau lesions were typically induced in vicinity of congophilic plaques in the
entorhinal cortex and hippocampus (Figure 5, E and F); however, in the amygdala there
was a clear separation with induced tau lesions in the basolateral part and amyloid
deposition in the dorso- and ventrolateral parts (Fig. 5, H). In areas not prone to develop
tau pathology in B6/P301L mice, such as the piriform and somatosensory cortex, there
was no or only modest tau pathology induction in the double-transgenic mice despite a
high plaque load (Figure 5G). In all mice congophilic amyloid deposits were surrounded
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by a robust activation of microglia and astroglia (not shown) similar to previous results in
APP23 mice [8,14].
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DISCUSSION
The present study was undertaken to confirm and expand previous in vivo studies
demonstrating a link between Aβ and the induction of neurofibrillary pathology [3,4]. We
have shown that tau pathology can be induced in the brain of young B6/P301L tau-
transgenic mice by a single injection of a dilute Aβ-containing extract, of a transgenic
APP23 mouse brain, but not by PBS, non-transgenic control extract or extract from a
transgenic B6/P301L mouse brain with tau lesions. These observations suggest that Aβ is
key to an effective induction of the tau pathology.
A similar induction of tau pathology, albeit only in the amyloid, has been described after
the infusion of synthetic Aβ1-42 into the somatosensory cortex and hippocampus of a tau
transgenic mouse model [4]. However, several important differences between the two
studies emerge. i) Gotz and colleagues [4] injected fibrillary synthetic Aβ  at a high
concentration (1 µg/µl) and the injected Aβ was readily detectable as amyloid and
persisted at the injection sites. In contrast, a highly dilute extract, with a 100- to 1000-
fold lower Aβ concentration (1 to 10 ng/µl) was used in the present study. ii) Gotz and
colleagues [4] used as host a mouse model (albeit with the same P301L mutation) that
develops tau pathology earlier (5 to 6 months of age) than the B6/P301L mouse model
used in the present study. This may explain the induction of tau lesions already 3 weeks
after the injection whereas in the present study analysis was done 6 months post-infusion.
iii) Gotz and colleagues, whereas reported that the induced tau lesions were Gallyas-
positive whereas the majority of the induced tau-lesion in the present study were Gallyas-
negative and of ‘pretangle’ stage. Again, this difference may be explained by the
difference in susceptibility of developing neurofibrillary lesions of the two transgenic
hosts or the concentration of the injected Aβ.
We have previously shown that extracts identical to the APP23 extracts have potent Aβ-
amyloid-inducing activity whereas synthetic Aβ did not reveal similar activity [6]. From
these results we suggested that the amyloid-inducing activity in brain represents a brain-
specific conformation or modification of Aβ that is different from synthetic Aβ. Thus
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from this latter study and the work of Gotz and colleagues [4], a dissociation of the Aβ-
amyloid-inducing activity and tau lesion-inducing activity of Aβ species could be
speculated, ie, synthetic Aβ is sufficient for the induction of the tau pathology but not for
the induction of Aβ-amyloid [6]. However, because of the above mentioned differences
between the present study and that of Gotz and colleagues [4], the conclusion that
synthetic Aβ and Aβ-containing brain extract are equally potent inducers of tau
pathology appears premature. Thus, to rigorously test the hypothesis of a dissociation of
the amyloid-inducing activity of Aβ from the neurofibrillary-inducing activity of Aβ,
future studies will be necessary in which brain extract versus synthetic Aβ will be tested
in the same transgenic model.
The observation that tau lesions were induced not only at the hippocampal injection site,
but also in remote areas such as entorhinal cortex and amygdala, and at the contralateral
sites might be explained by the axonal projections of these brain regions to the injection
site [4,15]. Various Aβ species are known to interact with synapses and to affect adversely
their structure and function [16], which in turn may lead to retrograde signaling, damage
and induction of tau lesions in the remote cell bodies. It is also possible that Aβ is taken
up and transported retrogradely to the soma where Aβ interacts with tau and induces tau
phosphorylation and aggregation [17-19]. Independent of the exact mechanism, the idea of
synaptic damage with retrogradely induced tau lesions might at least partly explain why
induction of tau lesions was found in the entorhinal cortex and amygdala but not in the
brain stem, which exhibits only diffuse projection to the injection sites. The lack of
induction of tau pathology in the somatosensory cortex may simply be a result of low
susceptibility of this region to form tau lesions in such tau transgenic mice [4,7,20]. In
addition, or alternatively to such a retrograde model of tau pathology propagation, the
infused Aβ may have been transported via blood and/or via interstitial fluid pathways to
the contralateral site and remote areas [21,22].
Tau pathology was also induced in B6/P301L transgenic mice when crossed with APP23
mice, confirming a previous study in which the same tau transgenic mouse model, albeit
on a mixed genetic background, was crossed with Tg2576 transgenic mice [3]. Although
in the infusion experiment exogenously applied Aβ species have triggered the tau
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pathology, in the double B6/P301L X APP23 transgenic mice, it may be argued that the
tau lesions were initiated by an intraneuronal (indirect) interaction of tau and Aβ, because
both the Thy1 promoter (in case of the APP23 mice) and PrP promoter (in case of the
B6/P301L mice) are expressed to a great extent in similar neuronal populations [23,24].
However, because the induction of the tau lesions appeared concomittant with the
appearance of significant cerebral amyloidosis, it is more likely that the extracellular
deposition of amyloid is the trigger of the neurofibrillary pathology.
The idea of a local induction of the tau pathology by the amyloid deposits is supported by
the current region-specific analysis of tau pathology induction versus amyloid load. The
most robust induction of tau pathology was in the entorhinal cortex, followed by
hippocampus, amygdala, and brain stem. Consistently, we found the highest plaque load
in the entorhinal cortex, followed by the hippocampus, the amygdala, and brain stem.
However, consistent with previous findings [3], neurofibrillary tangle bearing neurons
were not necessarily in close vicinity of the amyloid deposits exemplified in the
basolateral amygdala, with a robust induction of tau pathology but virtually no amyloid
deposition. These observations suggest that in the double transgenic mice tau induction in
areas without amyloid aggregates may be triggered from remote areas with amyloid
deposits similar to the suggested mechanism with the Aβ-containing brain extracts.
Although the infusion experiment strongly suggests Aβ species as being the trigger of the
induced tau pathology in remote areas, the mechanism of ‘local’ tau induction in the
crossed mice is more open for speculation. Congophilic amyloid deposition is always
accompanied by a strong neuroinflammatory response [14,25,26] and microglia activation
has recently been linked to the progression of tau pathology in transgenic mice [27]. It has
also been shown that congophilic plaques induce local axonal dystrophy and synaptic
abnormalities [15,28], which in turn may promote tau aggregation.
In conclusion, our results suggest that Aβ can induce neurofibrillary pathology by
different mechanisms. In particular the observation that infused Aβ can trigger the tau
pathology in the absence of amyloid deposits provides an explanation for the discrepancy
between the neuroanatomical location of amyloid deposits, or absence thereof, and the
development and spreading of tau lesions in AD brain.
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MATERIALS AND METHODS
Transgenic mice − Hemyzygous B6/P301L transgenic mice and non-transgenic wild-
type littermate controls were used. B6/P301L mice were obtained by backcrossing the
original P301L transgenic mice (JNPL3 mice) [7] with C57BL/6J mice for at least seven
generations. JNPL3 mice express the shortest four-repeat (4R0N) tau with the P301L
mutation under control of the mouse prion promoter. B6/P301L transgenic mice were
also crossbred with APP23 transgenic mice expressing human KM670/671NL mutant
APP [8].
Stereotaxic surgery − Host mice were anaesthetized with a mixture of ketamine (10
mg/kg body weight) and xylazine (20 mg/kg body weight) in saline. Unilateral
stereotaxic injections of 2.5 µl brain extracts were placed with a 5-µl Hamilton syringe
into the right neocortex (A/P, –2.5 mm from bregma; L, –2.0 mm; D/V, –0.8 mm) and
hippocampus (A/P, –2.5 mm from bregma; L, –2.0 mm; D/V, –1.8 mm). Injection speed
was 1.25 µl/minute, and the needle was kept in place for an additional 3 minutes before it
was slowly withdrawn. The surgical area was cleaned with sterile saline, and the incision
was sutured. Operated animals were monitored weekly in their cages for signs of
behavioural changes. No seizure activity was apparent during or after the infusion. All
experiments were in compliance with protocols approved by the local animal care and
use committee.
Preparation of brain extract − Brain extracts were prepared by first dissecting out the
neocortex of a 24 month-old APP23 transgenic female mouse (APP23 extract) and an
aged matched female non-transgenic littermate control.   Brain extract was also prepared
from the brainstem and diencephalon of a 21,5 month-old B6/P301L transgenic female
mouse (B6/P301L extract). Tissue samples were frozen and stored at –80°C until use.
The tissue pieces were then homogenized at 10% (w/v) in sterile phosphate-buffered
saline (PBS), vortexed, sonicated for 5 seconds, and centrifuged at 3000 X g for 5
minutes as previously described [6]. The supernatant was recovered and immediately
frozen (-80°C).
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Western blot analysis of brain homogenates − To determine Aβ levels in the brain
homogenates [9], samples were diluted 1 to 4 in sample buffer [0,48 mol/l Bis-Tris, 0,21
mol/l Bicine, 1,32 % (w/v) sodium dodecyl sulfate, 20 % (w/v) sucrose, 3,33 % (v/v) 2-
mercaptoethanol, 0,0053 % (w/v) bromophenol blue]. Samples were then subjected to 10
% Bicine-Tris 8 mol/l urea sodium dodecyl sulfate-polyacrilamide gel electrophoresis [10].
Synthetic Aβ1-40 and 1-42 (Bachem, Bubendorf, Switzerland) were used as controls.
Proteins were transferred onto a polyvinylidene difluoride membrane and probed with
monoclonal antibody 6E10 specific to human Aβ (diluted 1:500; Covance, Emeryville,
CA). The secondary antibody was horseradish peroxidase-conjugated goat anti-mouse
IgG (Chemicon, Temecula, CA). Bands were visualized using SuperSignal (Pierce,
Rockford, IL) and developed onto Kodak X-OMAT AR film (Eastman-Kodak,
Rochester, NY).
To determine tau levels in the brain homogenates, samples were dissolved in sample
buffer and run on 10 % sodium dodecyl sulfate-polyacrilamide gel electrophoresis Tris-
tricine gels. Proteins were electrophoretically transferred onto a polyvinylidene difluoride
membrane and probed with monoclonal antibody HT7 (diluted 1:1000, recognizes amino
acids 159 to 163 of tau phosphorylated and non phosphorylated epitopes; Pierce). The
secondary antibody was horseradish peroxidase-conjugated sheep anti-rabbit IgG
(NA931; Amersham-Biosciences, Uppsala, Sweden). Bands were visualized using
SuperSignal and developed onto Kodak X-OMAT AR film.
Histology and immunohistochemistry − Host mice were deeply anesthetized and they
were perfused transcardially with 4% paraformaldehyde in sodium phosphate buffer (pH
7.4) and processed for paraffin embedding. Immunohistological stainings were done on
5-µm coronal paraffin sections throughout areas of interest (see quantification), according
to standard procedures [11]. The following antibodies were used: monoclonal AT8
antibody (1:1000; Innogenetics, Gent, Belgium) specific to tau phosphorylated at ser-202
and thr-205; polyclonal anti-Aβ  antibody NT12 (1:1000; courtesy of P. Paganetti, Basel,
Switzerland) or DW6 (1:1000; courtesy of D. Walsh, Dublin, Ireland); polyclonal
antibody to GFAP (1:20000; Sigma Aldrich); and polyclonal antibody to Iba-1 (1:1000;
Wako, Neuss, Germany). Secondary antibodies were obtained from Vector Laboratories,
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Burlingame, CA (Vectastain ABC kits), for peroxidase staining. In addition sections were
stained histologically with silver-impregnation by the Gallyas protocol [12].
Stereological assessment of tau deposition − For selection of sampling sites for the
estimation of tau-immunopositive area fraction in the brain regions of interest
stereological sampling rules were applied [13]. Every 72th section through the
hippocampus (from positions AP -1.0 mm to AP – 4.0 mm from bregma), entorhinal
cortex (AP -2.5 mm to -4.0 mm), sensorimotor cortex (AP -1.0 mm to AP -3.5 mm),
amygdala (AP -1.0 mm to AP -3.5 mm), and brainstem (AP -4.0 mm to AP -5.0 mm) was
immunostained with AT8. Therefore, eight to nine sections through the hippocampus,
four to five through the entorhinal cortex, six to seven through the sensorimotor cortex
and amygdala, and two to three through the brain stem were analyzed per animal. The
brain regions were delineated at low magnification according to cytoarchitectural criteria
(Paxinos and Franklin, 1997). Within a single section, a systematic random sampling
scheme was performed to capture video images for measurement of AT8-positive
staining (percent area). All images were captured with an X40 objective using a Zeiss
Axioskop microscope (Zeiss, Göttingen, Germany) with a motorized x-y-z stage coupled
to a Sony CCD-IRIS color camera. To analyze the individual images for AT8-positive
burden, 24-bit color images (20 to 50 images per brain region) were converted to 8-bit
gray scale images by using conversion algorithms associated with Adobe Photoshop CS
(Adobe, San Jose, CA). Calculation of the percent area occupied by tau immunopositive
area fraction was performed using the public domain NIH ImageJ. Statistical analysis
included analysis of variance and post-hoc testing with the help of Statistica 5.0 (StatSoft,
Tulsa, OK).
Stereological assessment of amyloid deposition − To assess the burden of Aβ
deposition in brains, we have used the same stereological sampling as described above
for the assessment of AT8-positive deposits. Briefly, every 144th section through the
hippocampus (from positions AP -1.0 mm to AP -4.0 mm from bregma), neocortex (AP -
1.0 mm to AP -4.0 mm) amygdala (AP -1.0 mm to AP -3.5 mm) and brain stem (AP -4.0
mm to AP -5.5 mm) was immunostained with DW6. Therefore, four to five sections
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through the hippocampus and neocortex, three to four through the amygdala and one to
two through the brain stem were analyzed per animal. Using a systematic random
sampling scheme, images were captured with an X20 objective and converted to 8-bit
gray scale for calculating the percent area occupied by Aβ immunoreactive pixels.
Statistical analysis included analysis of variance and post-hoc testing with the help of
Statistica 5.0.
96
ACKNOWLEDGEMENTS
We thank Michael Calhoun (Tübingen, Germany) for helpful discussions and P.
Paganetti (Basel, Switzerland) and D. Walsh (Dublin, Ireland) for the generous donation
of antibodies.
97
REFERENCES
1. Goedert M., Spillantini M.G., A century of Alzheimer's disease. Science 2006,
314:777-781
2. Hardy J., Selkoe D.J., The amyloid hypothesis of Alzheimer's disease: progress
and problems on the road to therapeutics. Science 2002, 297:353-356
3. Lewis J., Dickson D.W., et al., Enhanced neurofibrillary degeneration in
transgenic mice expressing mutant tau and APP. Science 2001, 293:1487-1491
4. Gotz J., Chen F., van Dorpe J., Nitsch R.M., Formation of neurofibrillary tangles
in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001,
293:1491-1495
5. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M., Abeta
immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau
aggregates via the proteasome. Neuron 2004, 43:321-332
6. Meyer-Luehmann M., et al., Exogenous induction of cerebral beta-
amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784
7. Lewis J., et al., Neurofibrillary tangles, amyotrophy and progressive motor
disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000,
25:402-405
8. Sturchler-Pierrat C., et al., Two amyloid precursor protein transgenic mouse
models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997,
94:13287-13292
9. Herzig M.C., et al., Abeta is targeted to the vasculature in a mouse model of
hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004, 7:954-960
10. Wiltfang J., et al., Improved electrophoretic separation and immunoblotting of
beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis 1997,
18:527-532
11. Bondolfi L., et al., Amyloid-associated neuron loss and gliogenesis in the
neocortex of amyloid precursor protein transgenic mice. J Neurosci 2002, 22:515-
522
12. Gallyas F., Silver staining of Alzheimer's neurofibrillary changes by means of
physical development. Acta Morphol Acad Sci Hung 1971, 19:1-8
13. West M.J., Slomianka L., Gundersen H.J., Unbiased stereological estimation of
the total number of neurons in thesubdivisions of the rat hippocampus using the
optical fractionator. Anat Rec 1991, 231:482-497
14. Stalder M., et al., Association of microglia with amyloid plaques in brains of
APP23 transgenic mice. Am J Pathol 1999, 154:1673-1684
15. Phinney A.L., et al., Cerebral amyloid induces aberrant axonal sprouting and
ectopic terminal formation in amyloid precursor protein transgenic mice. J
Neurosci 1999, 19:8552-8559
16. Haass C., Selkoe D.J., Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8:101-
112
17. Busciglio J., Lorenzo A., Yeh J., Yankner B.A., beta-amyloid fibrils induce tau
phosphorylation and loss of microtubule binding. Neuron 1995, 14:879-888
98
18. Walker L.C., et al., Exogenous induction of cerebral beta-amyloidosis in
betaAPP-transgenic mice. Peptides 2002, 23:1241-1247
19. Guo J.P., Arai T., Miklossy J., McGeer P.L., Abeta and tau form soluble
complexes that may promote self aggregation of both into the insoluble forms
observed in Alzheimer's disease. Proc Natl Acad Sci U S A 2006, 103:1953-1958
20. Allen B., et al., Abundant tau filaments and nonapoptotic neurodegeneration in
transgenic mice expressing human P301S tau protein. J Neurosci 2002, 22:9340-
9351
21. Cirrito J.R., et al., In vivo assessment of brain interstitial fluid with microdialysis
reveals plaque-associated changes in amyloid-beta metabolism and half-life. J
Neurosci 2003, 23:8844-8853
22. Zlokovic B.V., Neurovascular mechanisms of Alzheimer's neurodegeneration.
Trends Neurosci 2005, 28:202-208
23. Borchelt D.R., et al., A vector for expressing foreign genes in the brains and
hearts of transgenic mice. Genet Anal 1996, 13:159-163
24. Calhoun M.E., et al., Neuronal overexpression of mutant amyloid precursor
protein results in prominent deposition of cerebrovascular amyloid. Proc Natl
Acad Sci U S A 1999, 96:14088-14093
25. Akiyama H., et al., Inflammation and Alzheimer's disease. Neurobiol Aging 2000,
21:383-421
26. Stalder A.K., et al., Invasion of hematopoietic cells into the brain of amyloid
precursor protein transgenic mice. J Neurosci 2005, 25:11125-11132
27. Yoshiyama Y., et al., Synapse Loss and Microglial Activation Precede Tangles in
a P301S Tauopathy Mouse Model. Neuron 2007, 53:337-351
28. Tsai J., Grutzendler J., Duff K., Gan W.B., Fibrillar amyloid deposition leads to
local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci
2004, 7:1181-1183
99
FIGURES LEGENDS
Figure 1. Tau pathology in heterozygous P301L tau transgenic mice on the genetic
C57BL6/J background (B6/P301L). (A, F) Overview picture taken from an AT8-stained
section shows the distribution of tau pathology in female B6/P301L mice at 12 months
(A) and 21 months (F) of age. (B-E) and (G-J) are high magnification pictures taken
from (A) and (F) and reveal in the 21 month-old but not 12 month-old mice a substantial
amount of tau lesions in the hippocampus (B , G; box top middle in A and F), lateral
entorhinal cortex (C , H ; box bottom right in A  and F), amygdala (D , I) and deep
mesencephalic nucleus (E, J; box top left in A and F). Inserts in I and J show Gallyas-
positive tangles, indicating that a large subset of the accumulating tau proteins form
insoluble aggregates. Bar in (G) is 100 µm. All panels have same magnification.
Figure 2. Histological and biochemical analysis of the injected brain extracts. (A) Aβ-
immunostaining of neocortex of a 24 month-old APP23 transgenic mouse, similar to the
one from which the extract was prepared, reveals extensive cerebral amyloid deposition.
(B) No amyloid was found in a non-transgenic age-matched littermate control brain. (C)
AT8-immunostaining of the brainstem of a female 21 month-old B6/P301L transgenic
mouse, similar to the one from which the tau extract was prepared, reveals numerous tau-
positive deposits. Bar is 50 µm. All panels have the same magnification. (D) Left:
Immunoblotting with antibody 6E10 specific to human Aβ: lane 1, synthetic Aβ1-40 and
1-42 (1ng/µl each); lane 2, APP23 brain extract, lane 3, non-transgenic APP23 littermate
control.  Right: Western blotting analysis with HT7 antibody specific to human tau: lane
1, AD brain extract reveals the various human tau isoforms (arrowheads); lane 2,
B6/P301L brain extract shows the transgenic 4R0N human isoform.
Figure 3. Intracerebral injection of Aβ-containing mouse brain extract induces tau
pathology in the hippocampus of young B6/P301L tau transgenic mice. Young 5-6
month-old B6/P301L transgenic mice and control littermates were injected unilaterally in
the hippocampus and overlying neocortex with various brain extracts and analyzed 6
months later. (A) Overview picture taken from an AT8-stained section shows the pattern
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of induced tau deposits throughout the injected hippocampus but also entorhinal cortex
(asterisk) of a B6/P301L transgenic mouse injected with the APP23 brain extract (the
injected site is the right one in the panel). (B) The injected hippocampal area, box in A, is
shown in higher magnification. (C) Injection with the non-transgenic control extract did
not induce tau pathology in the hippocampus. (D) Modest induction of tau pathology was
seen with the B6/P301L extract, while (E) no induced tau deposits were observed
following PBS injection. (F) When Aβ-containing APP23 extract was injected into a
non-transgenic B6/P301L mouse no tau lesions were induced. Bar is 100 µm.
Figure 4. Tau pathology induction in various regions in B6/P301L tau tg mice. (A)
Stereological analysis of % area occupied by AT8-positive staining (two-way ANOVA,
extract x hemisphere) in the hippocampus (HPS) confirms the significant induction of tau
deposition by the APP23 extract compared to PBS (+ n=5/group; p<0.0001; Newmann-
Keuls postdoc tests; indicated is SEM) and compared to the contralateral site (*
p<0.0001). Tau induction also occurred in some brain regions away from the injection
site, such as (B) the entorhinal cortex (ENT) and (C) the amygdala (AMG). Analysis
revealed again significant induction of the APP23 extract compared to PBS (+ n=5/group,
p<0.0001) and to the contralateral site (* p<0.05) which, for the amygdala also showed
some induction compared to PBS (p<0.001). No induced tau pathology was found in the
sensorimotor cortex (CTX) and brain stem (BS) (n=5/group; p>0.05). APP23=extract
from an aged APP23 mouse brain; WT=wild-type non-transgenic extract; P301L=extract
from an aged B6/P301L mouse brain.
Figure 5. Induced tau lesions in B6/P301LxAPP23 mice. (A, B) AT8-stained coronal
sections show tau pathology in the entorhinal cortex and adjacent CA1 field of an aged
male 28 mo-old double transgenic B6/P301L x APP23 mouse (A) while no pathology
was observed in a male aged-matched B6/P301L mouse (B). (C) Stereological analysis of
tau immunoreactivity (AT8 antibody) in the entorhinal cortex (ENT), hippocampus
(HPS), and amygdala (AMG) revealed tau induction in B6/P301L x APP23 transgenic
animals (n=7) compared to both single transgenic B6/P301L mice (n=7) and to APP23
littermates (n=4) (one-way ANOVA for genotype: * ENT, p<0.01; HPS, p<0.05; AMG,
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p<0.001; indicated is SEM) but not in the brain stem. (D) Stereological analysis of
amyloid load in the neocortex (CTX), hippocampus (HPS), amygdala (AMG) and brain
stem (BS) revealed no difference between the double transgenic mice and the single
APP23 transgenic littermates in any of the brain region analyzed (p>0.05). (E-H) High
magnification of an adjacent section to (A) double immunostained for AT8 and Aβ
shows the distribution of tau pathology in close vicinity of amyloid deposits in the
entorhinal cortex (E), and hippocampus (F) (see also boxed areas in A). In the pirform
cortex (G), and dorso- and ventrolateral amygdala (asteriks in H) no significant induction
of tau pathology was observed despite robust amyloid load. Notably in the basolateral
part of the amygdala substantial induction of tau lesions were observed (arrowheads in
H) although no significant amyloid deposition was apparent in this area. Bars are 75 µm.
Panels (E-G) have same magnification. (I) Gallyas silver staining shows that many of the
induced tau deposits in the entorhinal cortex were of fibrillary nature.
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Supplementary study
To determine whether neurofibrillary pathology can be induced in vivo by material
derived from human disease the previous study was extended by injection of brain
extracts derived from human patients with Alzheimer’s disease (AD). 5 to 6 month-old
B6/P301L mice were unilaterally injected with AD brain homogenates unilaterally into
the hippocampus and neocortex. To assess the importance of soluble Aβ species for
exogenous induction of tau pathogenesis, we injected AD extract with either low (brain
extract prepared from the amygdala) or high Aβ levels (brain extract prepared from the
frontal cortex) in parallel to the injection of brain extracts derived from old APP23- and
B6/P301L-transgenic mice.
Brain homogenates were prepared from the superior frontal cortex of an AD patient
(ADF extract) with both extensive β-amyloid deposition and NFT (Supplementary figure
1A), and from the amygdala (ADA extract) of an AD patient with extensive NFT but
almost complete absence of β-amyloid deposition (Supplementary figure 1B). Brain
homogenate was also prepared from an aged, β-amyloid-laden APP23 mouse
(Supplementary figure 1C) and from an aged, tau-depositing B6/P301L transgenic mouse
(Supplementary figure 1D). Western blotting confirmed significant Aβ levels (approx. 1-
10 ng/µl) in the ADF and APP23 extracts. The ADF extract contained significantly more
Aβ1-42 than Aβ1-40, while the APP23 mouse extract had more Aβ1-40 than Aβ1-42
(Supplementary figure 1E). Immunoblot analysis with human tau-specific antibody
detected all six human tau isoforms in the ADF and ADA human brain homogenates
(Supplementary figure 1F). The 4R0N human tau isoform was detected in extracts
prepared from an aged B6/P301L transgenic mouse consistent with the expression of this
shortest 4 repeat tau isoform in P301L transgenic mice (Supplementary figure 1F).
Intracerebral injection of Aβ-rich human ADF extract induced robust deposition of tau in
the hippocampus (assessed by phosphorylation-dependent AT8 antibody; Supplementary
figure 2A). Tau deposition was induced primarily throughout the injected hippocampus
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and, to a lesser degree, in the contralateral hippocampus (data not shown). In addition,
Tau pathology was also induced in brain regions farther away from the injection sites,
such as the amygdala (Supplementary figure 2B) and the entorhinal cortex
(Supplementary figure 2C). No tau deposits were observed around the injection site in the
neocortex (data not shown). ADF extracts injected into non-transgenic mice did not
induce any tau deposits, indicating that the expression of human tau was necessary for the
induction of tau lesions by the Aβ-containing extracts (data not shown).
Intracerebral injections of ADA extract induced only modest and non-significant tau
deposition (Supplementary figure 2D-F), consistent with the low β-amyloid load in the
tissue from which the extract was derived.
The finding that extracts with low Aβ levels have only modest tau-inducing activity
while extracts with high Aβ load reveals robust activity suggests that Aβ is key to an
effective induction of the tau pathology. Because the ADF extract (in which Aβ42
predominates) and the APP23 extract (in which Aβ40 predominates) were both potent
inducers of the tau pathology with qualitative and quantitative overall similar appearance,
it is likely that various Aβ  species of different length are potent in inducing
neurofibrillary pathology in vivo.
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Supplementary figure 1. Histological and biochemical characterization of the injected
extracts. (A) Gallyas staining of the superior frontal cortex of a 85 year-old AD patient
reveals amyloid plaques and neurofibrillary tangles. (B) Gallyas staining of basolateral
amygdala of a 96 year-old AD patient reveals significant neurofibrillary lesions but
almost no amyloid deposits. These sections were taken from an area directly adjacent to
the tissue from which the extracts (ADF = AD frontal cortex extract; ADA = AD
amygdala extract) were derived. (C) Aβ-immunostaining of neocortex of a 24 month-old
APP23 transgenic mouse. (D) Immunostaning with AT8 antibody reveals numerous tau-
positive deposits in the brainstem of a 21 month-old B6/P301L transgenic mouse. Bar in
(D) is 50 µm. All panels have same magnification. (E) Immunoblotting with antibody
6E10 specific to human Aβ: lane 1, synthetic Aβ1-40 and 1-42 (1ng/µl each); lane 2,
ADF brain extract; lane 3, ADA brain extract; lane 4: APP23 brain extract. (F) Western
blotting analysis with HT7 antibody specific to human tau: lane 1, ADF brain extract;
lane 2, ADA brain extract; lane 3, B6/P301L brain extract. Indicated are the various
human tau isoforms (arrowheads).   
Supplementary figure 2. Intracerebral injection of Aβ-containing human brain extract
induces tau pathology in B6/P301L tau tg mice. Adult 5-6 month-old B6/P301L
transgenic mice and control littermates were injected unilaterally in the hippocampus and
overlying neocortex and analyzed 6 months later. The ADF-injected B6/P301L mice
show an enhanced limbic neurofibrillary pathology in the hippocampus (A), Amygdala
(B), and entorhinal cortex (C). In contrast, injection with the ADA extract did not
significantly induce tau pathology in the brain of B6/P301L mice. Bar is 100 µm. All
panels have same magnification.
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SUPPORTING MATERIAL
Preparation of brain extract – Tissues for human brain extracts were derived at autopsy
from the superior frontal gyrus (ADF extract, patient 1) and the basolateral amygdala
(ADA extract, patient 2) of two female patients (85 and 96 years old; post mortem delays
7 and 11 hours; respectively) who have died of confirmed Alzheimer’s disease. The
tissue samples were fresh frozen and stored at -80°C until use. The tissue pieces were
then homogenized at 10 % (w/v) in sterile PBS, vortexed, sonicated for 5 seconds and
centrifuged at 3000x g for 5 minutes. The supernatant was aliquoted and immediately
frozen (-80°C).
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ABSTRACT
Tau protein in a hyperphosphorylated state makes up the filamentous intracellular
inclusions of several neurodegenerative diseases, including Alzheimer’s disease [1]. In the
disease process neuronal tau inclusions first appear in transentorhinal cortex, from where
they spread to hippocampal formation and neocortex [2]. Cognitive impairment becomes
manifest when inclusions reach the hippocampal formation, with abundant neocortical
tau inclusions and extracellular β-amyloid deposits being the defining pathological
hallmarks of Alzheimer’s disease. Abundant tau inclusions, in the absence of β-amyloid
deposits, define Pick’s disease, progressive supranuclear palsy, corticobasal degeneration
and other diseases [1]. Mutations in Tau cause familial forms of frontotemporal dementia,
establishing that dysfunction of tau protein is sufficient to cause neurodegeneration and
dementia [3-5]. Thus, transgenic mice that express mutant (e.g. P301S) human tau in nerve
cells exhibit the essential features of tauopathies, including abundant filaments made of
hyperphosphorylated tau protein and neurodegeneration [6,7]. In contrast, mouse lines
expressing single isoforms of wild-type human tau do not produce tau filaments or
display neurodegeneration [7,8]. Here we have used tau-expressing lines to investigate
whether experimental tauopathy can be transmitted. We show that the injection of brain
extract from mutant P301S tau-expressing mice into the brain of transgenic wild-type tau-
expressing animals induces the assembly of wild-type human tau protein into filaments
and the spreading of pathology from the site of injection to neighbouring brain regions.
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Transgenic mouse lines ALZ17 and P301S tau were used [6,8]. Mice from line
ALZ17, which express the longest human brain tau isoform (441 amino acids) do not
exhibit filamentous tau aggregates (Supplementary Fig. 1). By contrast, mice from line
P301S tau, which express the 383 amino acid human tau isoform with the P301S
mutation that causes inherited frontotemporal dementia, develop abundant filamentous
tau inclusions (Supplementary Fig. 1). Both the 383 and 441 amino acid tau isoforms
contain 4 microtubule-binding repeats, but they differ by the presence of 2 alternatively
spliced N-terminal inserts of 29 amino acids each [9].
To investigate whether aggregation of tau can be transmitted, we injected diluted
extracts of brainstem homogenates from 5 month-old human P301S tau mice into the
hippocampus and the overlying cerebral cortex of 3 month-old ALZ17 mice. Prior to
injection, the homogenates were analyzed by immunoblotting and immunoelectron
microscopy. Human tau protein bands of 55-64 kDa were detected by Western blotting
(Supplementary Fig. 2a). The slowest migrating tau species were immunoreactive with
antibody AT100 (Supplementary Fig. 2a) and other phosphorylation-dependent anti-tau
antibodies (not shown). By immunoelectron microscopy, tau filaments were present in
the tissue extracts (Supplementary Fig. 2b). Injection of brain extract from human P301S
tau mice induced filamentous tau pathology in ALZ17 mice, as indicated by the
appearance of Gallyas-Braak silver staining [10,11] (Fig. 1a,b) and the presence of tau
filaments by immunoelectron microscopy (Fig. 1c). Gallyas-Braak staining was present
intracellularly 6, 12 and 15 months after the injection of brain extract. In contrast, no
silver-positive lesions were observed in age-matched 18 month-old non-injected ALZ17
mice or in ALZ17 mice 15 months after the injection of brain extract from non-transgenic
control mice. In addition to silver-positive nerve cell bodies and processes, the injection
of brain extract from P301S tau mice resulted in the appearance of immunoreactivity with
antibody AT100, indicative of tau filaments [6]. In contrast to the absence of AT100
staining, AT8-immunoreactivity (reflecting tau hyperphosphorylation) was present in the
hippocampus of 18 month-old ALZ17 mice, as previously reported [8]. Following the
injection of brain extract from human P301S tau mice, AT8-immunoreactivity became
more widespread, indicating the promotion of tau hyperphosphorylation (Fig. 1a).
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Filamentous tau pathology in P301S tau-injected ALZ17 mice was induced in
different cell types. Silver-positive structures morphologically indistinguishable from
those found in human tauopathies were observed in the brains of injected ALZ17 mice
(Fig. 1b). They included neurofibrillary tangles (arrows in panels 1 and 2), neuropil
threads (arrowheads in panels 1 and 2) and oligodendroglial coiled bodies (arrows in
panels 3 and 4). The silver-positive structures were also immunoreactive for
phosphorylated tau (Fig. 1b, panels 2 and 3). Filaments extracted from injected brains
were decorated by phosphorylation-dependent anti-tau antibodies and by antibodies
specific for tau isoforms with N-terminal inserts (Fig. 1c). It follows that the filaments
had formed from the wild-type 441 amino acid human tau isoform expressed in line
ALZ17 and were not derived from the injected material. This is also consistent with the
observation that no silver staining was observed in ALZ17 mice 1 day after the injection
of P301S tau brain extract (not shown).
The induction of filamentous tau in ALZ17 mice was time- and brain region-
dependent. Quantitative assessment in the hippocampus revealed a significant increase in
the number of silver-positive lesions between 6, 12 and 15 months after injection (Fig. 2).
Neuropil threads were most abundant, followed by coiled bodies and neurofibrillary
tangles (Fig. 3). The same was true for the cerebral cortex, although fewer silver-positive
structures developed there over time (Fig. 2).
Positive silver staining did not remain confined to the injected areas, but spread
also to neighbouring brain regions (Fig. 4, Table 1). At the injection level, abundant
silver staining was present in subiculum, fimbria, optic tract and thalamus, with fewer
abnormal structures in more distant regions, such as medial lemniscus, zona incerta and
cerebral peduncle. The region most distant (4 mm ventral from the injection sites), where
filamentous tau pathology developed, was the hypothalamus. Almost 2 mm anterior to
the injection level, filamentous tau pathology was restricted to the fimbria and the
thalamus 6 months after injection, where it increased over time (Supplementary Fig. 3).
After 12 months, aggregated tau was found in the internal capsule, the caudate-putamen
and the somatosensory cortex. At 15 months post-injection, the hypothalamus and the
amygdala were also affected. More than 1 mm posterior to the injection level, the
cerebral peduncle, the hippocampus, the superior colliculus and the substantia nigra
118
exhibited filamentous lesions starting 6 months after the injection of brain extract from
human P301S tau mice (Supplementary Fig. 4). At 12 months, silver-positive structures
appeared in the entorhinal cortex and in the deep mesencephalic nucleus, before they
were seen in the pontine nuclei at 15 months. A small amount of filamentous tau
pathology was observed in some brain regions of the contralateral, non-injected
hemisphere (Supplementary Fig. 5).
The present findings show that the intracerebral injection of brain extract from
mice with a filamentous tau pathology induces the formation of silver-positive aggregates
made of hyperphosphorylated tau in mice transgenic for wild-type tau, demonstrating the
experimental transmission of tauopathy. From the increase in silver-positive structures
over time, it appears likely that nerve cell processes and oligodendrocytes are major sites
of filament induction. These findings are reminiscent of previous work using mouse
models of prion diseases, β-amyloid deposition and some peripheral amyloidoses [12-19].
However, unlike the extracellular location of filamentous deposits in those other diseases,
tau inclusions are intracellular. Mechanisms must therefore exist by which tau aggregates
can either gain access to the inside of cells or activate filament-inducing cascades from
the outside. Inside cells, tau aggregates could function as seeds for the ordered assembly
of transgenic wild-type human tau into silver- and AT100-positive filamentous deposits.
Intracellular filamentous tau pathology could also be induced by extracellular tau
aggregates. Previous work has indeed shown potentiation of tau pathology by
extracellular β-amyloid aggregates in mice transgenic for mutant human tau [15,16].
However, no such effect was observed in mice transgenic for wild-type human tau [20].
A combined neuronal and glial tau pathology is the defining feature of a number
of human neurodegenerative diseases characterized by the assembly of wild-type four-
repeat tau isoforms into filaments. They include progressive supranuclear palsy,
corticobasal degeneration and argyrophilic grain disease [21,22]. By contrast, in Pick’s
disease, three-repeat tau isoforms are found in the mostly neuronal inclusions and in
Alzheimer’s disease, both three- and four-repeat tau isoforms make up neurofibrillary
tangles [23,24]. In addition, the morphologies of tau filaments vary widely in different
tauopathies [25]. Together with the findings reported here showing transmission and
spreading of filamentous tau pathology, this is reminiscent of mammalian and yeast
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prions, for which different strains have been described, based on the existence of separate
conformers of assembled protein [26]. It is tempting to speculate that distinct tau strains
may underlie the pathogenesis of different sporadic tauopathies. This hypothesis can now
be tested experimentally by injecting ALZ17 mice with brain extracts from patients with
sporadic tauopathies.
During the process leading to Alzheimer’s disease, neuronal tau pathology forms
in a stereotypical fashion in transentorhinal cortex, from where it spreads to hippocampal
formation and neocortex [2], consistent with a uniform biological process. We also show
the appearance over time of silver-positive structures at sites that are at a distance from
the injection sites in hippocampus and cerebral cortex. Brain regions that develop
pathology are connected anatomically to the injection sites or to each other. This,
together with the stereotypical appearance of silver-positive structures in defined brain
regions over time (Table 1), is clearly indicative of the active induction and spreading of
pathology rather than passive diffusion of tau aggregates from the injection sites to more
distant regions.
It has been suggested that misfolded superoxide dismutase, which causes a subset
of familial forms of amyotrophic lateral sclerosis, is secreted from motor neurons [27]. By
analogy, spreading of tau pathology may also result from the release of aggregates from
affected nerve cells and glial cells. It will be important to investigate whether such
mechanisms exist for misfolded tau. In addition to active release mechanisms, the death
of nerve cells could also contribute to the accumulation of misfolded proteins in the
extracellular space and their uptake by neighbouring cells. The formation of tau
aggregates in a single brain cell and their subsequent spreading may therefore be at the
origin of sporadic tauopathies. Consequently, the presence of tau aggregates in the
extracellular space would be an obligatory step in the events leading to disease.
Immunisation strategies may prevent this process [28].
The present findings demonstrate the transmission of tauopathy between
transgenic mouse lines and describe an experimental system in which to investigate the
spreading of pathology and the existence of tau strains. It will be important to identify the
tau species capable of inducing transmission, aggregation and spreading. Similar
mechanisms may also underlie Parkinson’s disease and dementia with Lewy bodies,
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where α-synuclein pathology spreads from brainstem areas to midbrain and neocortex
[29]. Unlike prion diseases, human tauopathies are not believed to be infectious [30].
Experimental model systems of the type described here now make it possible to dissect
the similarities and differences between tauopathies and prion diseases.
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FIGURE LEGENDS
Figure 1. Induction of filamentous tau pathology in ALZ17 mice injected with brain
extract from mice transgenic for human P301S tau. (a) Staining of the hippocampal CA3
region from 18 month-old ALZ17 mice with anti-tau antibody AT8, Gallyas-Braak silver
or anti-tau antibody AT100. Non-injected (left), 15 months after injection with brain
extract from non-transgenic control mice (middle) and 15 months after injection with
brain extract from 5 month-old mice transgenic for human P301S tau protein (right). The
sections were counterstained with haematoxylin. Scale bar, 50 µm (same magnification in
all panels). (b) Different types of filamentous tau pathology are found in ALZ17 brains
injected with P301S tau brain extract: (1) neurofibrillary tangle (arrow) and neuropil
threads (arrowheads) visualized by silver staining; (2,3) double staining with silver and
AT8 (red) shows neurofibrillary tangles (2, arrows), neuropil threads (2, arrowhead) and
coiled bodies (3, arrow). (4) Double staining of coiled bodies (arrow) with silver and
antibody Olig2 (red). The sections were counterstained with haematoxylin. Scale bar, 50
µm (same magnification in all panels). (c) Immunoelectron microscopy of filaments
extracted from the brain of an ALZ17 mouse 15 months after the injection of brain
extract from mice transgenic for human P301S tau. Labelling with anti-tau sera 134, 189
and 304, and antibody AT100. Scale bar, 100 nm.
Figure 2. Temporal increase in the number of Gallyas-Braak-positive structures at the
injection sites (- 2.5 mm from bregma) in ALZ17 mice. A statistically significant increase
in silver-positive structures was observed in hippocampus between 6 and 12 months and
between 12 and 15 months. In cerebral cortex, a significant increase was present between
12 and 15 months. The results are expressed as means ± S.E.M. (n=5). *p<0.05.
Figure 3. Temporal increase in the number of neuropil threads, coiled bodies and
neurofibrillary tangles at the injection sites (- 2.5 mm from bregma) in ALZ17 mice.
Significant increases in neuropil threads and coiled bodies were observed between 6 and
12 months, and between 12 and 15 months. For neurofibrillary tangles, a significant
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increase was observed between 12 and 15 months. The results are expressed as means ±
S.E.M. (n=5). *p<0.05; **p<0.001; ***p<0.0001.
Figure 4. Spreading of filamentous tau pathology in ALZ17 mice injected with brain
extract from mice transgenic for human P301S tau. Gallyas-Braak silver staining of brain
regions at a distance from the injection sites 15 months post-injection. The sections were
counterstained with haematoxylin. Scale bar, 50 µm (same magnification in all panels).
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SUPPORTING MATERIAL
MATERIALS AND METHODS
Mice  – Homozygous human wild-type tau ALZ17 transgenic mice [8], homozygous
human P301S tau transgenic mice [6] and non-transgenic control mice, all females on a
C57BL/6J background, were used. Experiments were performed in compliance with
protocols approved by the local Basel Committee for Animal Care and Animal Use.
Preparation of brain extracts – Five month-old mice transgenic for human P301S tau
and age-matched non-transgenic control mice were deeply anaesthetized with
pentobarbital (100 mg/kg) and killed by decapitation. Brainstems were dissected, snap-
frozen in liquid nitrogen and stored at -80° C. Brainstems from 3 mice were combined
and homogenized at 10% (w/v) in sterile phosphate-buffered saline (PBS), sonicated
(Branson 450, output 2, 90% cycle = 5 times 0.9 s) and centrifuged at 3,000xg at 4° C for
5 min. The supernatants were aliquoted, snap-frozen and kept at -80° C until use.
Western blotting – Brain extracts were run on 8% tris-glycine SDS-PAGE transferred
onto a PVDF membrane (Immobilon P, Millipore, Zug, Switzerland) and probed with
anti-tau antibodies HT7 (1:1,000, Pierce, Rockford, IL), AT8 (1:1,000, Pierce) and
AT100 (1:200, Pierce). HT7 recognizes human, but not mouse tau [31], AT8 labels tau
phosphorylated at S202 and T205 [32], and AT100 detects tau phosphorylated at T212,
S214 and T217 [33]. The secondary antibody was goat anti-mouse IgG (Chemicon,
Temecula, CA). For signal detection, ECL plus (Amersham, Piscataway, NJ) was used in
conjunction with Amersham Hyperfilm ECL.
Stereotaxic surgery – Three month-old ALZ17 mice were anaesthetized with a mixture
of ketamine (10 mg/kg) and xylazine (20 mg/kg). When deeply anaesthetized, the mice
were placed on a heating pad to maintain body temperature during surgery. Using a
Hamilton syringe, the hippocampus (A/P, -2.5 mm from bregma; L, +/- 2.0 mm; D/V, -
1.8 mm) and the overlying cerebral cortex (A/P, -2.5 mm from bregma; L, +/- 2.0 mm;
D/V, -0.8 mm) each received a unilateral (right hemisphere) stereotaxic injection of 2.5
µl brain extract, at a speed of 1.25 µl/min. Following injection, the needle was kept in
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place for an additional 3 min before gentle withdrawal. The surgical area was cleaned
with sterile saline and the incision sutured. Mice were monitored until recovery from
anaesthesia and checked weekly following surgery.
Histology and immunohistochemistry – ALZ17 mice were deeply anaesthetized with
pentobarbital (100 mg/kg) and killed by transcardial perfusion with 20 ml cold PBS,
followed by 20 ml 4% paraformaldehyde in PBS. The brain was dissected and post-fixed
overnight. Following paraffin embedding, 5 µm coronal sections were prepared. Sections
were silver-impregnated following the method of Gallyas-Braak to visualize filamentous
tau pathology [9,10]. For immunohistochemistry, the following anti-tau antibodies were
used: T14 (1:1,000, Zymed, San Francisco, CA), AT8 (1:1,000) and AT100 (1:1,000).
T14 is specific for human tau [34]. Antibody Olig2 (1:500, Chemicon, Temecula, CA) was
used to stain oligodendrocytes. Secondary antibodies were from Vector Laboratories,
Burlingame, CA (Vectastain ABC kit).
Immunoelectron microscopy – Immunoelectron microscopy of injected P301S brain
extract using anti-tau antibody BR134 was performed as described [35]. BR134 was raised
against a synthetic peptide corresponding to amino acids 428-441 of tau (numbering
corresponding to the longest human brain tau isoform) [11]. In some experiments,
sarkosyl-insoluble tau was prepared from injected ALZ17 brains, as described [24]. Anti-
tau antibodies BR134, BR189, BR304 and AT100 were used to identify tau filaments.
BR189 and BR304 were raised against amino acids 76-87 and 45-73 of tau, respectively
[24]. They are specific for tau isoforms with one (BR304) or two (BR304 and BR189) N-
terminal inserts.
Quantitative analysis of tau pathology – Five ALZ17 mice injected with P301S brain
extract were analyzed at 6, 12 and 15 months post-injection. Gallyas-stained coronal
sections were selected at identical brain coordinates [36] (anterior to the injection level, -
0.82 mm from bregma; injection level, - 2.5 mm from bregma; posterior to the injection
level, - 3.8 mm from bregma). Silver-positive structures (neurofibrillary tangles, neuropil
threads and coiled bodies) were counted at these 3 levels with a x20 objective (Zeiss,
132
Feldbach, Switzerland). At the injection level (- 2.5 mm from bregma), total counts of
silver-positive structures were assessed in the injection sites hippocampus (CA1, CA2,
CA3, dentate gyrus and subiculum) and visual cortex. In the visual cortex, silver-positive
lesions developed just around and at a very short distance from the needle tract.
Statistical analysis was performed using the Poisson regression algorithm with the help of
the SAS 8.02 software. Link function was the logarithm and scale was estimated by
deviance (to account for overdispersion). For semi-quantitative assessment, Gallyas-
Braak staining was graded as follows: (-), no silver-positive structures; (+), < 20 silver-
positive structures; (++), 20-40 silver-positive structures; (+++), > 40 silver-positive
structures.
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LEGENDS OF SUPPLEMENTARY FIGURES
Figure 1. Lines ALZ17 and P301S tau. Staining of cerebral cortex, hippocampus and
brainstem of an 18 month-old ALZ17 mouse (left) and a 5 month-old mouse transgenic
for human P301S tau (right). Note the absence of silver staining in the ALZ17 mice and
the strong staining in the P301S mouse. The sections were counterstained with
haematoxylin. Scale bar, 50 µm (same magnification in all panels).
Figure 2. Characterization of mouse brain extracts. (a) Immunoblotting of mouse brain
extracts with anti-tau antibodies HT7 (specific for human tau, phosphorylation-
independent) and AT100 (phosphorylation-dependent). Lanes: 1, brainstem extract (125
µg tissue) from non-transgenic control mice; 2, brainstem extract used for injection (125
µg tissue) from mice transgenic for human P301S tau; 3, forebrain extract (125 µg tissue)
from 18 month-old ALZ17 mice; 4, recombinant human tau isoform mixture (10 ng). (b)
Immunoelectron microscopy using anti-tau serum BR134 to decorate filaments in the
brain extract used for injection. Scale bar, 100 nm.
Figure 3. Spreading of filamentous tau pathology anterior to the injection level. (a,b)
Gallyas-Braak staining of the fimbria from ALZ17 mice injected with P301S brain
extract (- 0.82 mm from bregma) 6 months (a) and 15 months (b) after the injection of
brain extract from mice transgenic for human P301S tau. The sections were
counterstained with haematoxylin. Scale bar, 50 µm (same magnification in all panels).
Figure 4. Spreading of filamentous tau pathology posterior to the injection level. (a,b)
Gallyas-Braak staining of the polymorphic layer of the hippocampus from ALZ17 mice
injected with P301S brain extract posterior (- 3.8 mm from bregma) to the injection site 6
months (a) and 15 months (b) after the injection of brain extract from mice transgenic for
human P301S tau. The sections were counterstained with haematoxylin. Scale bar, 50 µm
(same magnification in all panels).
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Figure 5. Modest contralateral spreading of filamentous tau pathology. (a,b) Gallyas-
Braak staining of the ipsilateral (a) and contralateral (b) fimbria of an ALZ17 mouse 15
months after the unilateral injection of brain extract from mice transgenic for human
P301S tau (injection level). Note the few scattered silver-positive lesions in the
contralateral side (arrow). The sections were counterstained with haematoxylin. Scale
bar, 50 µm (same magnification in all panels).
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5. CONCLUSION
Tau, which is abundantly expressed in both central and peripheral nervous system, binds
to and stabilizes microtubules as fundamental structures for neuronal integrity. For
currently unknown reasons, Tau becomes abnormally phosphorylated and aggregates in
many ‘tauopathies’, clinically characterized by dementia and/or movement disorders.
Pathological Tau detaches from microtubules, which in turn disassemble, leading to cell
death.
Alzheimer’s disease (AD), the most common form of dementia in the elderly, is
histologically characterized not only by intracellular aggregation of Tau but also by the
extracellular deposition of Amyloid-β (Aβ) peptide [1, 2]. In cases of familial AD, the
‘Amyloid cascade’ hypothesis holds that production of Aβ deposits precedes and triggers
Tau pathology [2, 3, 4]. In this thesis, we have first validated this hypothesis by using
different experimental approaches taking the advantage of transgenic mouse models.
Through lentivirus-mediated expression of P301S mutant Tau in both wild-type and
APP23 mice we have obtained stable Tau expression for up to thirteen months.
Neurofibrillary tangles were that way induced in APP23 mice; in contrast, Tau remained
in a hyperphosphorylated state in wild-type animals, validating the pathogenic influence
of Aβ on the induction of neurofibrillar Tau pathology [5].
Using a ‘seeding’ approach it has been shown previously that injection of Aβ42 fibrils
into the somatosensory cortex of Tau P301L mice results in the formation of NFTs in the
amygdala, a region projecting to the injection site [6]. In the present thesis, we confirmed
this finding by injection of dilute brain extract from aged, Aβ-laden APP23 transgenic
mice into the brains of young B6/P301L Tau transgenic mice. Six months after injection,
Tau pathology was induced not only in the injected hippocampus but also in the
entorhinal cortex and amygdala, areas with neuronal projections to the injection site [7].
These data additionally support the hypothesis that Aβ-induced damage of presynaptic
terminals or axons that project to the injection site may cause subsequent NFT formation
in respective somatic compartments.
Transgenic mouse models of AD, where mutant APP is expressed, develop senile plaques
but fail to reproduce neurofibrillary Tau pathology probably due to the lack of human
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Tau expression. To overcome this problem, transgenic mice expressing mutant APP have
been bred with the transgenic JNPL3 mice carrying the P301L Tau mutation [8].
Interestingly, Aβ pathogenesis was not modified in double transgenic animals compared
to single APP-transgenic mice, but the density of NFTs was significantly higher than in
single JNPL3 Tau-transgenic female animals [8]. We confirmed these findings by
crossbreeding our B6/P301L Tau-transgenic mice with APP23-transgenic animals. In our
double transgenic mice, NFTs were induced in males whereas B6/P301L single-
transgenic males did not develop Tau pathology up to 30 months of age. In addition,
double-transgenic female mice showed an acceleration of Tau pathology that appeared
more pronounced when compared to the original B6/P301L single-transgenic mouse
model [7]. Collectively, our findings demonstrate that filamentous Tau pathology can be
exogenously induced by Aβ deposition and provide further evidence for the putative
effect of Aβ as a causative pathogenic factor of AD.
In AD, Tau pathology spreads within the brain following a stereotypical pattern, which is
clinically paralleled by a progressive cognitive decline but occurs independently of
development and spreading of Aβ deposits [9, 10, 11]. In addition, somewhat contradictory
to the ‘Amyloid cascade’ hypothesis, most tauopathies -devoid of any Aβ deposition-
feature pathological Tau lesions and even exhibit an intriguing spatiotemporal spreading
of Tau pathology [12, 13, 14, 15]. Furthermore, mutations in the Tau gene identified in FTDP-
17 patients demonstrate that Tau dysfunction per se is sufficient to cause
neurodegeneration [16, 17, 18]. However, the conditions by which Tau dysfunction leads to
neurodegeneration and dementia are poorly understood, especially in the absence of
detectable Aβ deposition. To investigate a potential role of Tau in the initiation and
spreading of Tau pathology, we have performed seeding studies. We injected brain
homogenates from aged Tau-depositing P301S mice into the somatosensory cortex and
the hippocampus of young ALZ17 mice which transgenically express wild-type human
Tau but do not develop filamentous Tau deposits. Significantly, injected ALZ17 animals
developed a robust filamentous Tau pathology that increased with time and appeared in
regions with neuronal projections to the injection sites. These results demonstrate for the
first time the experimental transmission and spreading of tauopathy in transgenic mouse
lines and open up new perspectives for future studies aimed at dissecting the fibrillogenic
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agent present in the P301S extract. Moreover, injection of brain extracts from human
sporadic tauopathies would allow to elucidate their potentially infectious nature and thus
also enable to compare similarities and differences between tauopathies and prion
diseases. Last but not least, therapeutic strategies such as immunotherapy-based
approaches could be tested in such experimental seeding models to prevent the process of
Tau fibril formation [19].
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ABBREVIATIONS
Aβ Amyloid-beta peptide
AD Alzheimer’s disease
AgD Argyrophilic grain disease
APP Amyloid precursor protein
CA Cornu ammonis
CAA Cerebral amyloid angiopathy
CamKII Calcium/calmodulin-dependent kinase II
CBD Corticobasal degeneration
Cdk5 Cyclin-dependent kinase 5
CNS Central nervous system
C-terminal Carboxy-terminal
DM Myotonic dystrophy
EMEA European agency for the evaluation of medication
ERK2 Extracellular signal-regulated kinase 2
FAD Familial Alzheimer’s disease
FDA Food and drug administration
FTDP-17 Frontotemporal dementia with parkinsonism linked to chromosome 17
GSK3β Glycogen synthase kinase 3β
MAPK Mitogen-activated protein kinase
MARK Microtubule-affinity-regulating kinase
NFT(s) Neurofibrillary tangles
N-terminal Amino-terminal
Non-PDPK Non-proline-directed protein kinase
NSAIDs Non-steroidal anti-inflammatory drugs
NT(s) Neuropil threads
PDPK Proline-directed protein kinase
PHF(s) Paired-helical filament
PiD Pick’s disease
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PIP2 Phosphatidylinositol 4,5 bisphosphate
PKA cAMP-dependent kinase
PLC Phospholipase C-γ
PNS Peripheral nervous system
PP(s) Protein phosphatase
PS Presenilin
PSP Progressive supranuclear palsy
SAPK/JNK Stress-activated C-Jun N-terminal kinase
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